US3629243A - 14alpha 17alpha-methylenedioxypregnane derivatives - Google Patents
14alpha 17alpha-methylenedioxypregnane derivatives Download PDFInfo
- Publication number
- US3629243A US3629243A US831824A US3629243DA US3629243A US 3629243 A US3629243 A US 3629243A US 831824 A US831824 A US 831824A US 3629243D A US3629243D A US 3629243DA US 3629243 A US3629243 A US 3629243A
- Authority
- US
- United States
- Prior art keywords
- dione
- dihydroxy
- pregnene
- acetate
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003431 steroids Chemical class 0.000 abstract description 12
- 229910052799 carbon Inorganic materials 0.000 abstract description 4
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical group C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 abstract description 3
- 150000003128 pregnanes Chemical class 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 description 58
- 238000002844 melting Methods 0.000 description 38
- 230000008018 melting Effects 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- -1 BF -etherate Chemical class 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 15
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 14
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- JHKNNJGCLLEOBK-DOBITEAFSA-N (1R,2S,8R,9R,12S,13S)-8-ethyl-9,13-dimethyl-4,6-dioxapentacyclo[10.8.0.02,9.03,7.013,18]icosane Chemical class C1OC2[C@@H]3[C@]([C@H](C2O1)CC)(C)CC[C@H]1[C@H]3CCC3CCCC[C@]13C JHKNNJGCLLEOBK-DOBITEAFSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- BTOAYZVUZVTWMC-JTPZPXLFSA-N C1CC2CCCC[C@]2(C)[C@@H](CC[C@]23C)[C@@H]1[C@]31CC[C@@]2(CC)OCO1 Chemical class C1CC2CCCC[C@]2(C)[C@@H](CC[C@]23C)[C@@H]1[C@]31CC[C@@]2(CC)OCO1 BTOAYZVUZVTWMC-JTPZPXLFSA-N 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical class C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 7
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 7
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000006356 dehydrogenation reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 150000003126 pregnane derivatives Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 5
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GUHFLRTWNHWJBS-VLTGGNAYSA-N (8r,9s,10s,13s)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1C1=CC=C(C(=O)C)[C@@]1(C)CC2 GUHFLRTWNHWJBS-VLTGGNAYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- 241000122824 Aspergillus ochraceus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 2
- 229960003868 paraldehyde Drugs 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XMRPGKVKISIQBV-UHFFFAOYSA-N (+-)-5- Pregnane-3,20-dione Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 XMRPGKVKISIQBV-UHFFFAOYSA-N 0.000 description 1
- MBJJLHWSFGHIAA-UDCWSGSHSA-N (8s,9s,10r,13s,14s,17s)-10,13-dimethyl-17-(2,2,2-trihydroxyacetyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)C(O)(O)O)[C@@H]4[C@@H]3CCC2=C1 MBJJLHWSFGHIAA-UDCWSGSHSA-N 0.000 description 1
- VOYADQIFGGIKAT-UHFFFAOYSA-N 1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidine-5-carboximidamide Chemical compound CCCCn1c(O)c(C(N)=N)c(=O)n(CCCC)c1=O VOYADQIFGGIKAT-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 1
- WKAVAGKRWFGIEA-DADBAOPHSA-N 11-Ketoprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2=O WKAVAGKRWFGIEA-DADBAOPHSA-N 0.000 description 1
- WKAVAGKRWFGIEA-UHFFFAOYSA-N 11-Ketoprogesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2=O WKAVAGKRWFGIEA-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000010216 Cunninghamella blakesleeana Species 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000203720 Pimelobacter simplex Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150113676 chr1 gene Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- DLZVZNAPRCRXEG-UHFFFAOYSA-N methyl 4-oxobutanoate Chemical compound COC(=O)CCC=O DLZVZNAPRCRXEG-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229940070805 p-chloro-m-cresol Drugs 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ORBIGZZHMAJXAZ-UHFFFAOYSA-N pyridine-4-carbonyl pyridine-4-carboxylate Chemical compound C=1C=NC=CC=1C(=O)OC(=O)C1=CC=NC=C1 ORBIGZZHMAJXAZ-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/913—Aspergillus
Definitions
- the invention relates to new therapeutically useful steroids of the pregnane series, to processes for their preparation and to pharmacological compositions containing them.
- R represents an whydIOgen atom or an a-halogen atom
- R represents an tat-hydrogen atom and a B-hydroxyl group or a B-halogen atom or R represents an 0X0 group, and R represents a hydrogen atom or an acyl group.
- the carbon atoms 14 and 17 of the steroid skeleton are bridged by one carbon atom and two oxygen atoms that are arranged in such a way that they form a 1,3-dioxane ring system with the carbon atoms 14, 13 and 17 of the steroid skeleton.
- the pregnane derivatives of Formula 1 are therapeutically useful compounds possessing anti-infiammatory activity. These properties make the compounds of the invention useful in the treatment of allergic and rheumatic disorders and of various skin diseases. These compounds can be applied for human as well as veterinary uses; they can be administered orally as well as parenterally; they can also be applied locally, f.i. on the skin.
- Preferred compounds of Formula 1 are those wherein R represents a straight or branched chain alkyl group, which group has less than 5 carbon atoms, or a phenyl group, which group may be substituted (preferably in the para-position) by a halogen, preferably a chlorine atom, a lower alkyl or lower alkoxy, preferably methoxy group, or a phenyl(lower)alkyl 'group, a cyclopropyl, furyl or thienyl group; R represents an tit-hydrogen atom or an iii-halogen, preferably chlorine or bromine atom, R represents an tit-hydrogen atom and a B-hydroxyl group or when R represents a chlorine atom R represents an DL-hydI'OgCIl atom and a ti-halogen, preferably chlorine atom;
- the 14a,17a-methylenedioxypregnane derivatives of Formula 1 may be prepared by methods known for the preparation of analogous compounds.
- the pregnane derivatives of Formula 1 are prepared by reacting a 14a,17a-dihydroxypregnane derivatives of the formula CHgORl hi on V/ wherein the various symbols are as hereinbefore defined, with an aldehyde of the formula R CHO or its acetal of the formula R CH(OR wherein R is as hereinbefore defined and R represents a lower alkyl group.
- R in Formula 2 represents a hydrogen atom
- the 21-hydroxyl group is preferably protected, e.g. by esterification, before these reactions are carried out.
- reaction of a l4u,l7a-dihydroxypregnane derivative of Formula 2 with an aldehyde of the formula R CHO is preferably conducted at room temperature using a strong acid as catalyst and, if desired, in an inert organic medium.
- a strong acid as catalyst and, if desired, in an inert organic medium.
- an acetal of the formula R CH(OR) it has been found suitable to carry the reaction out at a temperature between 20 C. and C. in the presence of a strong acid as catalyst; the lower alcohol is distilled off as it is formed, if necessary under reduced pressure (Tetrahedron Letters 1961, 448).
- Compounds of Formula 1, wherein the 6-7 position is saturated may be converted into the corresponding G-dehydro derivatives with chloranil or 2,3-dichloro-S,6- dicyanobenzoquinone.
- chloranil When chloranil is used, the reaction is preferably carried out in a solvent boiling between 30 C. and (3.; usually the reactants are heated at the boiling temperature of the solution (I.A.C.S. 81 (1959), 5991 and 82 (1960), 4293).
- Suitable solvents are for example: ethanol, tert-butanol, tert-pentanol, methyl acetate, dioxane, tetrahydrofuran, glacial acetic acid, benzene and acetone.
- Pregnane derivatives of Formula 1, wherein the 1-2 position is saturated can be converted into the corresponding l-dehydro-derivatives according to the usual chemical or microbiological processes.
- Appropriate chemical dehydrogenating agents are 2,3-dichloro-5,6-dicyanobenzoquinone and selenium dioxide.
- the 1,2-dehydrogenation by means of 2,3-dichloro-5,6-dicyanobenzoquinone can be carried out in the same solvents as used in the 6-7 dehydrogenation with chloranil. It is advisable to add to the reaction mixture a small amount of nitrophenol. Depending on the solvent applied and the starting material used the reaction will take 1.5 to 48 hours to be completed (Proc. Chem. Soc.
- microbiological l-dehydrogenation can be brought about by appropriate microorganisms, such as Corynebacterium simplex (J.A.C.S. 77 (1955), 4184), Bacillus splzaericus (Arch. Bioch. 59 1955), 304) and Fusarium solani (Helv. Chim. Acta 38 (1953), 835).
- the starting material is added to a submerged culture of the utilized microorganism, which is grown in a suitable nutrient medium at an optimal temperature with strong aeration. Instead of this fermentation culture, suspensions of the microorganisms in buffered solutions may be used. The conversion is followed chromatographically and the fermentation fluid is extracted e.g. with dichloromethane, upon complete conversion of the starting material.
- the 6 dehydrogenation reaction with 2,3-dichloro-5,6- dicyanobenzoquinone which is conducted in the presence of a strong acid is therefore preferably carried out after the 1411- and Not-hydroxyl groups of the pregnane derivative of Formula 2 have been converted into a l4zx,l7ocmethylenedioxy group according to the processes described above.
- an ll-hydroxyl group can be introduced in manner known per se in a 14a,17adihydroxypregnane derivative of formula 2 as well as in a 14a,17a-methylenedioxypregnane derivative of Formula 1 wherein the ll-position is unsubstituted and the other symbols are as thereinbefore defined.
- a hydroxyl group can be introduced at the ll-position of 14a,l7a-methyldioxypregnane derivatives of Formula 1, wherein the ll-position is unsubstituted and the various other symbols are as hereinbefore defined through appropriate microorganisms.
- Suitable microorganisms are Curvullu'ia blakesleeana (J.A.C.S. 77 (1955), 763), CluminglIa/nella blukesleemla (J.A.C.S. 75 (1953), 5369),
- the starting material is a 21-ester the acyl group may be split off since microorganisms that have hydroxylating properties tend to have hydrolyzing activity also.
- the starting material either suspended in water or dissolved in a suitable solvent, as e.g. acetone or dimethyl formamide, is added to a submerged culture of the microorganism used, which is grown in a suitable nutrient medium at an optimal temperature with strong aeration. The conversion is followed chromatographically. Upon complete converison of the starting material the fermentation fluid is filtered and the filtrate is extracted, e.g. with methyl isobutyl ketone.
- the ll-hydroxy pregnane derivatives thus formed can be used as starting materials in the preparation of the corresponding 11-oxo derivatives; the ll-hydroxy compounds, wherein the 21-position should be protected, f.i. by esterification, when R represents a hydrogen atom, can be oxidized for example, by means of CrO in acetic acid.
- the ll-hydroxy pregnane derivatives prepared according to the methods described above can also be used in the preparation of corresponding 9a-halo llfi-hydroxy and 9a,11fi-dihalo compounds.
- an ll-hydroxy pregnane compound of Formula 1 wherein the 9-position is unsubstituted, is converted into the corresponding 9(l)-dehydro derivative by splitting off one molecule of water.
- Compounds wherein the ll-hydroxyl group is in the fl-position are reacted thereto with thionyl chloride or with methane sulphonyl chloride in pyridine (Helv. Chim. Acta 43 (1960), 145 and J. Org. Chem. 25 (1960), 295).
- the 11- hydroxyl group of the starting material is in the a-position this hydroxyl group is first converted into an ester group, f.i.
- the 21-hydroxyl group in pregnane derivatives of Formula 1 wherein R represents a hydroxyl group is protected, f.i. by esterification, during these reactions.
- the 9(ll)-dehydropregnane compounds prepared according to the above process can be converted into the corresponding 9a,11/3-dihalo derivatives by addition of two halogen atoms at the double bond 9(11); for example, the 9a,11fi-dichloro derivatives can be prepared by reacting the corresponding 9(11)-dehydro compound with N-chlorosuccinimide and hydrogen chloride (Steroids 7 (1966), 234 and J.A.C.S. 82 (1960), 2308 and 4001).
- the 14a,1Wat-methylenedioxypregnane derivatives of Formula 1 wherein R R and R are as hereinbefore defined and R represents a hydrogen atom, may be converted into the corresponding 21-esters by one of the usual esterification methods.
- the carbonic acid esters can be prepared by reaction of the 21- hydroxy derivative with a carbonic acid an hydride or a carbonic acid chloride in pyridine (Helv. Chim.
- the phosphoric acid esters can be prepared by reaction with fl-cyanoethyl phosphate and dicyclohexyl carbodiimide in pyridine and the sulphuric acid esters by reaction with (CH NSO in pyridine (Steroids 6 (I965), 247).
- the 1401,1711- methylenedioxypregnane derivatives of Formula 1 wherein R R and R are as hereinbefore defined and R represents an acyl group may be converted into the corresponding 21-hydroxyl derivatives by methods known per se, for instance, by alcoholysis by means of sodium methanolate and methanol.
- Typical compounds of the present invention are:
- pregnadiene-3,20-dione 1 15,2 1-dihydroxy-9a-chloro-14a, 17a-ethylidenedioxy 1,4-
- the compound of Formula 2 wherein R and R each represents an a-hydrogen atom and R represents a hydrogen atom can be obtained by microbiological conversion of Reichsteins Compound S, i.e. 17a,21-dihydroxy-4-pregnene-3,20-dione.
- Suitable microorganisms are for example Absidia regnieri (Chem. & Pharm. Bu-l. Japan 9 (1961), 59), Cunninghamella blakesleeana (Vit. & Horm. 14 (1956), 359) and Helminlhosporium avenae (J. Agr. Chem. Soc. Japan 34 (1960), 762 and 35 (1961), 521).
- Another suitable starting material in the process of the invention is the known compound 14a-hydroxy-hydrocortisone (Dutch Pat. No. 95,601).
- the corresponding Ila-isomer of 14a-hydroxy hydrocortisone can be obtained by microbiological conversion of the derivative l4a-hydroxy-Compound S, the preparation of which has been indicated above.
- f.i. Aspergillus ochraceus there is obtained the desired compound, i.e. 11a,14a,l7a,21-tetrahydroxy-4-pregnene- 3,20-dione.
- EXAMPLE 1 A mixture of 5.0 g. of l4a-hydroxy-hydrocortisone 2l-acetate, 5 ml. of paraldehyde, 1.3 ml. of perchloric acid (70% 3 ml. of water and 30 ml. of purified dioxane was kept for 46 hours at room temperature. To the reaction mixture 500 ml. of methyl isobutyl ketone were added and the resulting solution was successively washed with mmole of a solution of potassium carbonate in water and subsequently three times with 50 ml. of water. The solvent was completely removed by distillation under reduced pressure. The residue was crystallized from methanol, yielding 3.2 g.
- CHCI3) 7 LR. (in CHC13) r,,,,, 3612, 1745, 1730, 1660, 1615,
- EXAMPLE 4 In an analogous way to the procedure described in Example 1, l4a-hydroxy-hydrocortisone 2l-acetate was converted with butanal to l15,2l-dihydroxy-l4oc,l7a-butylidenedioxy-4-pregnene-3,20-dione 2l-acetate.
- EXAMPLE 6 A mixture of 7.2 g. of 14ot-hydroxy-hydrocortisone 21- acetate, 40 ml. of nonanal, 160 ml. of methylene chloride and 2 ml. of perchloric acid (70%) was stirred for 6 hours and refluxed. The reaction mixture was successively washed with solutions of sodium sulphite and of sodium carbonate in water and with water. The methylene chloride layer thus purified was evaporated to dryness and the residue was crystallized from diethyl ether. The precipitate consisting of 3.9 g. of the by-product 14-dehydro-hydrocortisone 21- acetate was filtered off.
- EXAMPLE 7 A mixture of 5.0 g. of 14a-hydroxy-hydrocortisone 21- acetate, 5.0 ml. of dimetllylsulphoxide, 1.6 ml. of perchloric acid (70%) and 40 m1. of p-isopropylbenzaldehyde was stirred for 7 days at room temperature. The reaction mixture was diluted with 150 m1. of methylene chloride and was successively washed with solutions of sodium bisulphite and of sodium carbonate in water and with water. The organic layer was evaporated to dryness. The residue was subjected to column chromatography (silica gel, eluent benzene/ acetone 3:1). 0.50 g.
- EXAMPLE 8 A mixture of 8.0 g. of 14a-hydroxy-hydrocortisone 21- acetate, 24 g. of 3-(methoxycarbonyl)-propanal, 1.0 ml. of perchloric acid (70% and ml. of methylene chloride was kept for 3 days at room temperature. The reaction mixture was worked up as usual and the residue obtained was purified by chromatography (aluminium oxide, activity III, eluent benzene/ethyl acetate 2:1). 0.75 g. of 11B,21dihydroxy-l4a,17a-(3 methoxycarbonylpropylidenedioxy)-4-pregnene-3,20-dione ZI-acetate was isolated.
- EXAMPLE 1 1 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 2l-acetate was converted with p-chlorobenzaldehyde to 1113,21-dihydroxy- 14a,17a (p-chlorobenzylidenedioxy) 4-pregnene-3,20- dione 21-acetate.
- EXAMPLE 12 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with p-methoxybenzaldehyde to 11 8,21-dihydroxy 1441,1711.-(p-methoxybenzylidenedioxy) 4-prcgnene 3,20-dione 21-acetate.
- EXAMPLE 13 In an analogous way to the procedure described in Example 9, l4a-hydroxy hydrocortisone 21-acetate was converted with a-naphthaldehyde to 11,8,21-dihydroxy 14oz, 17a-(1'-naphthylmethylenedioxy) 4-pregnene-3,20-dione 21-acetate.
- EXAMPLE 14 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with cyclohexylformaldehyde to 116,21-dihydroxy 14a,17a-(cyclohexylmethylenedioxy)-4-pregnene- 3,20-dione 21-acetate.
- EXAMPLE 15 In an analogous way to the procedure described in Example 9, 14ahydroxy hydrocortisone 21-acetate was converted with 3-phenylpropanal to 1118,21-dihydroxy 14oz, 174x-(3'-phenylpropylidene dioxy) 4-pregnene-3,20-dione 21-acetate.
- EXAMPLE 17 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with isovaleraldehyde to 11B,21-dihydroxy-14a, 17cc (3' methylbutylidenedioxy)-4-pregnene-3,20-dione 2l-acetate.
- EXAMPLE 18 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with benzaldehyde to 11/3,21-dihydroxy-14a,17abenzylidenedioxy-4-pregnene-3,20-dione 21-acetate.
- EXAMPLE 19 A solution of 22.0 g. of l1B,21-dihydroxy-14u,17oethylidenedioxy 4 pregne'ne-3,20-dione 21-acetate prepared according to the process of Example 1 and 14.3 g. of 2,3-dichloro 5,6-dicyanobenzoquinone in 200 m1. of dioxane was stirred at 95 C. After 1.5 h. the precipitate formed; 12.9 g. of the benzoquinone, was filtered off and was thoroughly washed with methylene chloride. The filtrate was stirred for 30 min. with 40 g. of aluminum oxide that had been acidified (30 ml. of acetic acid (10%)/kg. aluminum oxide.
- EXAMPLE 21 In a similar way to the procedure described in Example 19, 11B,21-dihydroxy-14u,17u-ethy1idenedioxy-1,4,6- pregnatriene-3,20-dione ZI-acetate was obtained from 116, 21 dihydroxy 14a,17a-ethylidenedioxy-4,6-pregnadiene- 3,20-dione 21-acetate (prepared according to the process of Example 20) by reaction with 2,3-dichloro-5,6- dicyanobenzoquinone.
- EXAMPLE 22 (A) A solution of 4.3 g. of llfi,2l-dihydroxy-l4a,l7uethylidenedioxy-1,4-pregnadiene-3,2O dione 21 acetate prepared according to the process of Example 19 in 30 ml. of tetrahydrofuran and 22 m1. of pyridine was cooled down to -10 C. With stirring and continued cooling 2.9 ml. of thionyl chloride were cautiously added drop- Wise. The ensuing suspension was rapidly brought to 0 C. After 15 minutes the reaction mixture was poured into 600 ml. of water, to which 5 g. of sodium chloride had been added. 4.0 g. of amorphous 21-hydroxy-14a- 17oz ethylidenedioxy 1,4,9(11)-pregnatriene-3,20-dione 21-acetate were obtained.
- EXAMPLE 24 A nitrogen-flushed solution of 15.6 g. of 1119,21-dihydroxy-14a,17a-ethylidenedioxy-4-pregnene 3,20 dione 21-acetate prepared according to the process of Example 1 in a mixture of 125 ml. of methylene chloride and 125 ml. of methanol was treated with 1.4 ml. of 1.0 N sodium methoxide in methanol. The reaction mixture was left standing for 45 min. at room temperature, was then neutralized with 0.2 ml. of acetic acid and evaporated to dryness. The residue was crystallized from methanol to yield 9.4 g. of 11B,21-dihydroxy-14a,17aethylidene-dioxy-4-pregnene 3,20 dione. From the mother liquid, 1.7 g. of this compound was isolated.
- EXAMPLE 29 In an analogous way to the procedure described in Example 28, 11B,21-dihydroxy-14a,17ot butylidenedioxy- 4-pregnene-3,20-dione 2l-(1'-adamanty1)carboxylate was prepared from 115,21-dihydroxy-14a,l7a-butylidenedioxy-4-pregnene-3,20-dione prepared according to the process of Example by reaction with l-adamantylcarbonyl chloride.
- EXAMPLE 33 In an analogous way to the procedure described in Example 28, 116,21-dihydroxy-14u,l7a-butylidenedioxy- 4-pregnene-3,20-dione 2l-isonicotinate was prepared from 116,21 dihydroxy 14a,17u-butylidenedioxy-4-pregnene- 3,20-dione prepared according to the process of Example 25 by reaction with isonicotinic acid anhydride.
- EXAMPLE 34 (A) According to the process described in Example 1, 14a,17ot,21 trihydroxy-4-pregnene-3,20-dione 21-acetate was converted with paraldehyde to 21-hydroxy-14a,17aethylidenedioxy-4-pregnene-3,20-dione 21-acetate.
- the micro-organism was grown at 26 C. with vigorus shaking and aeration. After 24 h. a solution of 3 g. of 21 hydroxy-14a,17ot-ethylidenedioxy-4-pregnene-3,20-dione prepared according to the above process in ml. of dimethyl formamide was added. Within 48 h. the conversion was complete. The mycelium was filtered off and washed with water. The filtrate and the washing were combined and thrice extracted with 2 l. of methyl isobutyl 17 ketone. The extract was evaporated to dryness under reduced pressure, the residue was crystallized from methanol/water.
- EXAMPLE 35 (A) In an analogous way to the procedure described in Example 34C, 21 hydroxy 140:,170: ethylidenedioxy-4- pregnene-3,20-dione prepared according to the processes of Examples 34A and B was converted with Aspergillus ochraceus to 11all-dihydroxy-14a,17a-ethylidenedioxy- 4-pregnene-3,20-dione.
- Example 28 According to the process described in Example 28 the compound thus obtained was converted with acetic anhydride to 1101,21 dihydroxy 1411,17 a ethylidenedioxy4- pregnene-3,20-dione 21-acetate.
- the extract was washed with an aqueous hydrogen carbonate solution and water and evaporated to dryness in vacuo.
- the residue was taken up in a little benzene and separated on a silica gel column (700 g. of silica gel; eluentzbenzene/ acetone 11:1). The fractions containing the product were combined and evaporated to dryness in vacuo.
- the residue was crystallized from methyl isobutylketone; yield: 5.2 g. of 21 hydroxy-14a,17a-ethylidenedioxy-4-pregnene-3,11, ZO-trione 21-acetate.
- EXAMPLE 36 A solution of 4 g. of 21-hydroxy 14a,17a-ethylidenedioxy-4-pregnene-3,11,20-trione 21-acetate prepared according to the processes of Example 35 in 40 ml. of methylene chloride was saturated with nitrogen for 30 minutes. 1 ml. of 1 N solution of sodium methoxide in methanol was added and the mixture was stirred at room temperature in a nitrogen atmosphere. The conversion was complete within 20 minutes (thin layer chromatography). The mixture was neutralized and evaporated to dryness. After crystallization from methyl isobutyl ketone/diethyl ether the residue yielded 2.2 g.
- the invention includes within its scope pharmaceutical preparations containing, as the active ingredient, at least one of the therapeutically active compounds of the general formula according to fig. 1 in association with a pharmaceutically acceptable carrier.
- the preparations may take any of the forms customarily employed for administration of therapeutically active substances, but the preferred types are those suitable for oral administartion, especially tablets, including sustained release tablets, pills and capsules including the substance, those suitable for parenteral administration and those for local application.
- the tablets and pills may be formulated in the usual manner with one or more pharmaceutically acceptable diluents or excipients, and include materials of lubricating nature.
- Capsules made of absorbable material, such as gelatin may contain the active substance alone or in admixture, with a solid or liquid diluent.
- Liquid preparations may be in the form of suspensions, emulsions, syrups, or elixirs of the active substance in water or other liquid medium commonly used for making orally acceptable pharmaceutical formulations.
- the active substance may also be made up in a form suitable for parenteral administration, i.e. as a suspension or emulsion in sterile water or an organic liquid usually employed for injectable preparations, for example a vegetable oil such as corn or olive oil, or a sterile solution in water or an organic solvent.
- the active substance may also be made up in creams, ointments and lotions suitable for local application. These preparations may be formulated in the usual manner with one or more pharmaceutically acceptable diluents or excipients. The preparation of a suitable cream for local application is described in the following example.
- the steroid (particle size below lO t) was brought in suspension in the 1 ml. aqueous solution that was set apart and this mixture was added to the cream obtained. The mixture was homogenized during 30 minutes in a homogenizor.
- the concentration of the active compound of Formula 1 in the creams, ointments and lotions may vary between 0.01% and 1%.
- each tablet may contain from 0.25 mg. to 25 mg. of the active substance.
- Suitable daily dosages to humans consist of 1 to 4 tablets.
- suspensions for intramuscular administration or solutions for intravenous administration concentrations may vary from 5 to 25 mg./ml., while the daily dosage in human application will vary from 1 to 2 ml.
- the concentration of the active substance in injectable preparations may vary from 0.1 to ing/ml.
- Daily dosages 1 to 2 ml. for dogs and cats 1 to 3 ml. for pigs 10 to ml. for cows and horses.
- R represents (a) a straight or branched chain aliphatic hydrocarbon group, which group has less than 9 carbon atoms and may be substituted by a loweralkoxycarbonyl group,
- R represents an tat-hydrogen atom or an ot-halogen atom
- R represents (a) an a-hydrogen atom together with a fl-hydroxyl group or a B-halogen atom or (b) an oxo group
- R represents a hydrogen atom or an acyl group of an organic carboxylic acid.
- R represents a methyl, ethyl, propyl, butyl, Z-methylpropyl or propenyl group.
- 140:,170 methylenedioxypregnane derivative according to claim 1 in which the derivative is llpLZI-dihydroxy-14a,17a-nonylidenedi0xy 4-pregnene 3,20 dione 21-acetate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
14A,17A - METHYLENEDIOXYPREGNANE DERIVATIVES WHICH HAVE ANTI-INFLAMMATORY ACTIVITY ARE PROVIDED. IN THE NEW PREGNANE COMPOUNDS, POSITIONS 14 AND 17 OF THE STEROID NUCLEUS ARE BRIDGED BY A CARBON ATOM AND TWO OXYGEN ATOMS, FORMING A 1,3-DIOXANE RING WITH CARBON ATOMS 14, 13 AND 17 THE STEROID NUCLEUS.
Description
US. Cl. 260239.55 D 41 Claims ABSTRACT OF THE DISCLOSURE l4a,17a methylenedioxypregnane derivatives which have anti-inflammatory activity are provided. In the new pregnane compounds, positions 14 and 17 of the steroid nucleus are bridged by a carbon atom and two oxygen atoms, forming a 1,3-dioxane ring with carbon atoms 14, 13 and 17 of the steroid nucleus.
BACKGROUND OF THE INVENTION The invention relates to new therapeutically useful steroids of the pregnane series, to processes for their preparation and to pharmacological compositions containing them.
SUMMARY OF THE INVENTION According to the present invention there are provided new 14oz,l7a-methylenedioxypregnane derivatives of the formula CHR1 in which the dotted lines in the positions 12 and 6-7 indicate, as is conventional, the optional presence of another bond, and wherein R represents (a) a straight or branched chain aliphatic hydrocarbon group, which group has less than 9 carbon atoms and may be substituted by a (lower)alkoxy carbonyl group, (b) an aryl group, which aryl group has less than 11 carbon atoms and may be substituted by halogen atoms, lower alkyl, and lower alkoXy groups, (c) an aryl (lower alkyl) group, (d) a cycloalkyl group having 3 to 6 carbon atoms, (e) the furyl group, or (f) the thienyl group;
R represents an whydIOgen atom or an a-halogen atom;
R represents an tat-hydrogen atom and a B-hydroxyl group or a B-halogen atom or R represents an 0X0 group, and R represents a hydrogen atom or an acyl group.
As will be apparent from Formula 1, the carbon atoms 14 and 17 of the steroid skeleton are bridged by one carbon atom and two oxygen atoms that are arranged in such a way that they form a 1,3-dioxane ring system with the carbon atoms 14, 13 and 17 of the steroid skeleton.
The pregnane derivatives of Formula 1 are therapeutically useful compounds possessing anti-infiammatory activity. These properties make the compounds of the invention useful in the treatment of allergic and rheumatic disorders and of various skin diseases. These compounds can be applied for human as well as veterinary uses; they can be administered orally as well as parenterally; they can also be applied locally, f.i. on the skin.
nited States Patent 0 3,629,243 Patented Dec. 21, 1971 DESCRIPTION OF THE PREFERRED EMBODIMENTS Preferred compounds of Formula 1 are those wherein R represents a straight or branched chain alkyl group, which group has less than 5 carbon atoms, or a phenyl group, which group may be substituted (preferably in the para-position) by a halogen, preferably a chlorine atom, a lower alkyl or lower alkoxy, preferably methoxy group, or a phenyl(lower)alkyl 'group, a cyclopropyl, furyl or thienyl group; R represents an tit-hydrogen atom or an iii-halogen, preferably chlorine or bromine atom, R represents an tit-hydrogen atom and a B-hydroxyl group or when R represents a chlorine atom R represents an DL-hydI'OgCIl atom and a ti-halogen, preferably chlorine atom; and R represents a hydrogen atom or an organic acyl group.
The 14a,17a-methylenedioxypregnane derivatives of Formula 1 may be prepared by methods known for the preparation of analogous compounds.
According to a process of the invention the pregnane derivatives of Formula 1 are prepared by reacting a 14a,17a-dihydroxypregnane derivatives of the formula CHgORl hi on V/ wherein the various symbols are as hereinbefore defined, with an aldehyde of the formula R CHO or its acetal of the formula R CH(OR wherein R is as hereinbefore defined and R represents a lower alkyl group. When R in Formula 2 represents a hydrogen atom, the 21-hydroxyl group is preferably protected, e.g. by esterification, before these reactions are carried out.
The reaction of a l4u,l7a-dihydroxypregnane derivative of Formula 2 with an aldehyde of the formula R CHO is preferably conducted at room temperature using a strong acid as catalyst and, if desired, in an inert organic medium. (Chem. & Ind. (London) 1961, 465); in case an acetal of the formula R CH(OR is employed, it has been found suitable to carry the reaction out at a temperature between 20 C. and C. in the presence of a strong acid as catalyst; the lower alcohol is distilled off as it is formed, if necessary under reduced pressure (Tetrahedron Letters 1961, 448).
Preferred catalysts are perchloric acid, p-toluene-sulphonic acid and hydrochloric acid. Lewis acids, such as BF -etherate, or salts, such as CuSO or ZnCl are also suitable. As solvents, for example, halogenated alkanes, methyl acetate, ethyl acetate, dioxane, tetrahydrofuran, benzene or dimethylformamide can be used.
When a compound of Formula 1 is obtained with one of these processes, it can be converted, if desired, into another derivative belonging to the class of compounds defined by Formula 1 in manner known per se.
Compounds of Formula 1, wherein the 6-7 position is saturated, may be converted into the corresponding G-dehydro derivatives with chloranil or 2,3-dichloro-S,6- dicyanobenzoquinone. When chloranil is used, the reaction is preferably carried out in a solvent boiling between 30 C. and (3.; usually the reactants are heated at the boiling temperature of the solution (I.A.C.S. 81 (1959), 5991 and 82 (1960), 4293). Suitable solvents are for example: ethanol, tert-butanol, tert-pentanol, methyl acetate, dioxane, tetrahydrofuran, glacial acetic acid, benzene and acetone. The same solvents can be used when carrying the reaction out with 2,3-dichloro-5,6- dicyanobenzoquinone instead of with chloranil; it is then preferred to conduct the reaction in the presence of a strong acid, such as p-toluene sulphonic acid; the reactants are usually heated at the boiling temperature of the solution (Chem. & Ind. 1962, 211).
Pregnane derivatives of Formula 1, wherein the 1-2 position is saturated, can be converted into the corresponding l-dehydro-derivatives according to the usual chemical or microbiological processes. Appropriate chemical dehydrogenating agents are 2,3-dichloro-5,6-dicyanobenzoquinone and selenium dioxide. The 1,2-dehydrogenation by means of 2,3-dichloro-5,6-dicyanobenzoquinone can be carried out in the same solvents as used in the 6-7 dehydrogenation with chloranil. It is advisable to add to the reaction mixture a small amount of nitrophenol. Depending on the solvent applied and the starting material used the reaction will take 1.5 to 48 hours to be completed (Proc. Chem. Soc. 1960, 14). Using selenium oxide most suitable solvents are tert-butanol, ethyl acetate or tert-pentanol. The reaction can be accelerated by addition of small amounts of glacial acetic acid. Also this conversion is preferably conducted at the boiling temperature of the solution. The reaction is completed within about -48 hours (J.A.C.S. 81 (1959), 1235 and 5991).
The microbiological l-dehydrogenation can be brought about by appropriate microorganisms, such as Corynebacterium simplex (J.A.C.S. 77 (1955), 4184), Bacillus splzaericus (Arch. Bioch. 59 1955), 304) and Fusarium solani (Helv. Chim. Acta 38 (1953), 835). The starting material is added to a submerged culture of the utilized microorganism, which is grown in a suitable nutrient medium at an optimal temperature with strong aeration. Instead of this fermentation culture, suspensions of the microorganisms in buffered solutions may be used. The conversion is followed chromatographically and the fermentation fluid is extracted e.g. with dichloromethane, upon complete conversion of the starting material.
Some of the dehydrogenating reactions described above can also be carried out with the 14a,17a-dihydroxypregnane derivatives of Formula 2, wherein the various symbols are as hereinbefore defined and the 1-2 and/or the 6-7 positions are saturated. However, reactions which are conducted under strongly acidic conditions are preferably carried out after the 14a,Not-dihydroxypregnane derivatives have been converted into the corresponding 14oz,17ot-methylenedioxypregnane derivatives since under these conditions water may be split off at the l4-position.
The 6 dehydrogenation reaction with 2,3-dichloro-5,6- dicyanobenzoquinone which is conducted in the presence of a strong acid is therefore preferably carried out after the 1411- and Not-hydroxyl groups of the pregnane derivative of Formula 2 have been converted into a l4zx,l7ocmethylenedioxy group according to the processes described above. The same situation arises when other substituents are introduced to prepare the pregnane derivatives of Formula 1. For example, an ll-hydroxyl group can be introduced in manner known per se in a 14a,17adihydroxypregnane derivative of formula 2 as well as in a 14a,17a-methylenedioxypregnane derivative of Formula 1 wherein the ll-position is unsubstituted and the other symbols are as thereinbefore defined. The same applies to most of the other reactions described herebelow where, for convenience sake, reference is made only to starting materials wherein the substituted 14a,17a-methylenedioxy group is already present.
A hydroxyl group can be introduced at the ll-position of 14a,l7a-methyldioxypregnane derivatives of Formula 1, wherein the ll-position is unsubstituted and the various other symbols are as hereinbefore defined through appropriate microorganisms. Suitable microorganisms are Curvullu'ia blakesleeana (J.A.C.S. 77 (1955), 763), CluminglIa/nella blukesleemla (J.A.C.S. 75 (1953), 5369),
4 Aspergillus oclzraceus (Mycologia 47 (1955), 464) and Rhizopus migricans (J.A.C.S. 75 (1953), 408).
In case the starting material is a 21-ester the acyl group may be split off since microorganisms that have hydroxylating properties tend to have hydrolyzing activity also. To accomplish the ll-hydroxylation, the starting material, either suspended in water or dissolved in a suitable solvent, as e.g. acetone or dimethyl formamide, is added to a submerged culture of the microorganism used, which is grown in a suitable nutrient medium at an optimal temperature with strong aeration. The conversion is followed chromatographically. Upon complete converison of the starting material the fermentation fluid is filtered and the filtrate is extracted, e.g. with methyl isobutyl ketone.
The ll-hydroxy pregnane derivatives thus formed can be used as starting materials in the preparation of the corresponding 11-oxo derivatives; the ll-hydroxy compounds, wherein the 21-position should be protected, f.i. by esterification, when R represents a hydrogen atom, can be oxidized for example, by means of CrO in acetic acid.
The ll-hydroxy pregnane derivatives prepared according to the methods described above can also be used in the preparation of corresponding 9a-halo llfi-hydroxy and 9a,11fi-dihalo compounds.
First, an ll-hydroxy pregnane compound of Formula 1, wherein the 9-position is unsubstituted, is converted into the corresponding 9(l)-dehydro derivative by splitting off one molecule of water. Compounds wherein the ll-hydroxyl group is in the fl-position are reacted thereto with thionyl chloride or with methane sulphonyl chloride in pyridine (Helv. Chim. Acta 43 (1960), 145 and J. Org. Chem. 25 (1960), 295). When the 11- hydroxyl group of the starting material is in the a-position this hydroxyl group is first converted into an ester group, f.i. with p-toluene sulphonic acid or with methane sulphonic acid. The ester group is then removed again by means of sodium acetate in glacial acetic acid or with lithium chloride in dimethyl formamide whereby, simultaneously, a double bond between the carbon atoms at the positions 9 and 11 is formed (J.A.C.S. 79 (1957), 1130 and Helv. Chim. Acta 42 (1959), 2548).
Preferably, the 21-hydroxyl group in pregnane derivatives of Formula 1 wherein R represents a hydroxyl group is protected, f.i. by esterification, during these reactions.
By reacting the 9(l1)-dehydropregnane compounds thus formed with f.i. HClO or HBrO the corresponding 9a-halo llfi-hydroxy pregnane derivatives can then be prepared (J.A.C.S. 77 (1955), 4181 and 80 (1958), 2338).
Similarly, the 9(ll)-dehydropregnane compounds prepared according to the above process can be converted into the corresponding 9a,11/3-dihalo derivatives by addition of two halogen atoms at the double bond 9(11); for example, the 9a,11fi-dichloro derivatives can be prepared by reacting the corresponding 9(11)-dehydro compound with N-chlorosuccinimide and hydrogen chloride (Steroids 7 (1966), 234 and J.A.C.S. 82 (1960), 2308 and 4001).
The 14a,1Wat-methylenedioxypregnane derivatives of Formula 1 wherein R R and R are as hereinbefore defined and R represents a hydrogen atom, may be converted into the corresponding 21-esters by one of the usual esterification methods. For example, the carbonic acid esters can be prepared by reaction of the 21- hydroxy derivative with a carbonic acid an hydride or a carbonic acid chloride in pyridine (Helv. Chim. Acta 34 (1951), 354); the phosphoric acid esters can be prepared by reaction with fl-cyanoethyl phosphate and dicyclohexyl carbodiimide in pyridine and the sulphuric acid esters by reaction with (CH NSO in pyridine (Steroids 6 (I965), 247). Alternatively, the 1401,1711- methylenedioxypregnane derivatives of Formula 1 wherein R R and R are as hereinbefore defined and R represents an acyl group, may be converted into the corresponding 21-hydroxyl derivatives by methods known per se, for instance, by alcoholysis by means of sodium methanolate and methanol.
When preparing 14a,17ot-methylenedioxypregnane derivatives of Formula 1 from the corresponding 14a,17adihydroxy compounds of Formula 2, theoretically speaking, a mixture of two stereoi somers can be expected, since bridging the 1411- and 17a-oxygen atoms by a substituted methylene group introduces a new asymmetric carbon atom. Up to now the occurrence of two isomers has not been demonstrated however. As determined from the data of paper and thin layer chromatography, melting points, optical rotations and N.M.R. spectra of the products obtained, two isomers do not appear to have been formed.
Typical compounds of the present invention are:
1 15,21-dihydroxy-14a,17a-ethylidenedioxy-4-pregnane- 3,20-dione 1 15,21-dihydroxy-14a,17a-ethylidenedioxy-4-pregnene- 3,20-dione 2l-acetate 115,2l-dihydroxy-l4oz,17a-(3'-methylbutylidenedioxy)- 4-pregnene-3 ,20-dione 1 15,21-dihydroxy-14a,17a-hefxylidenedioxy-4-pregnene- 3,20-dione 21-acetate 115,21-dihydroxy14a,17a-(2-penteny1idenedioxy)-4- pregnene-3 ,20-dione 1 15,21-dihydroxy-14a,17a-(4'-methoxycarbonylbutylidenedioxy -4-pregnene-3,20-dione 1 15,21-dihydroxy-14a,17u-benzylidenedioxy-4-pregnene-3,20-dione 21-acetate 115,2l-dihydroxy-1411,17-(2'-phenylethylidenedioxy)- 4-pregnene3,20-dione 115,21-dihydroxy-140:,17ot-(2-furylmethylenedioxy)- 4-pregnene-3,2(l-dione 21-isonicotinate 115,21-dihydroxy-14a,17a-(2'-furylmethylenedioxy) 4-pregnene-3 ,ZO-dione 2 1- 3 '-phenyl) propionate 115,21-dihydroxy- 14a,17w(2-furylmethylenedioxy) 4-pregnene-3,20-dione 2l( l'-adamantyl) carboxylate 115,21-dihydroxy-14u,17a-(2-furylmethylenedioxy)- 4-pregnene-3 ,20-dione 2 l-pivalate 1 15,21-dihydroxy-140:,17a-(2-furylmethylenedioxy)- 4-pregnene-3 ,20-dione 21-decanoate 1 15,21-dihydroxy-14tx,17u-cyclopropylmethylenedioxy- 4-pregnene-3,20-dione 21-isonicotinate 1 15,21-dihydroxy-l4a,17a-cyclopropylmethylenedioxy- 4-pregnene-3,20-dione 21 3 -phenyl propionate 1 15,21-dihydroxy-14a,17ot-cyclopropylmethylenedioxy- 4-pregnene-3,20-dione 21-( 1'-adamantyl carboxylate 1 15,2l-dihydroxy-14a,17a-cyclopropylmethylenedioxy- 4-pregnene-3,20-dione 21-pivalate 1 15,21-dihydroxy-14a,17a-cyclopropylmethylenedioxy- 4-pregnene-3 ,ZO-dione 2l-decanoate 21-hydroxy-14a,17a-ethylidenedioxy-9ot,l l5-dichloro- 1,4-pregnadiene-3 ,20-dionc 21-hydroxy-14a,l7u-ethylidenedioxy-9u,l l5-dichloro- 1,4-pregnadiene-3,ZO-dione 21-isonicotinate 21-hydI'OXy-140L,170L-6thY1ld6116dlOXY-9ot,1113-(11011101'0- 1,4-pregnadiene-3 ,20-dione 21-(3 -phenyl propionate 21-hydroxy-14a,17u-ethylidenedioxy-4-pregnene- 3,1 1,20-trione 2l-pivalate 2 l-hydroxy-14a,17a-ethylidenedioxy-4-pregnene 3 ,1 1,20-
trione 2 1- 1 -adamantyl carboxylate 1 15,2l-dihydroxy-9a-chloro-14a,17a-ethylidenedioxy 1,4-
pregnadiene-3,20-dione 1 15,2 1-dihydroxy-9a-chloro-14a, 17a-ethylidenedioxy 1,4-
pregnadiene-3,20-dione 21-isonicotinate The 14a,17a-dihydroxypregnene compounds of Formula 2 which are used as starting material in the processes of the invention are known compounds or can be prepared according to methods known for the preparation of analogous compounds.
For example the compound of Formula 2 wherein R and R each represents an a-hydrogen atom and R represents a hydrogen atom, i.e. 14m,17u,21-trihydroxy-4-pregnene-3,20-dione, can be obtained by microbiological conversion of Reichsteins Compound S, i.e. 17a,21-dihydroxy-4-pregnene-3,20-dione. Suitable microorganisms are for example Absidia regnieri (Chem. & Pharm. Bu-l. Japan 9 (1961), 59), Cunninghamella blakesleeana (Vit. & Horm. 14 (1956), 359) and Helminlhosporium avenae (J. Agr. Chem. Soc. Japan 34 (1960), 762 and 35 (1961), 521).
Another suitable starting material in the process of the invention is the known compound 14a-hydroxy-hydrocortisone (Dutch Pat. No. 95,601). The corresponding Ila-isomer of 14a-hydroxy hydrocortisone can be obtained by microbiological conversion of the derivative l4a-hydroxy-Compound S, the preparation of which has been indicated above. Upon treatment of this derivative with f.i. Aspergillus ochraceus there is obtained the desired compound, i.e. 11a,14a,l7a,21-tetrahydroxy-4-pregnene- 3,20-dione.
These 14a,17a-dihydroxypregnene compounds thus prepared can be converted again in other derivatives of Formula 2, generally in the same manner as described above for the corresponding conversions of the 14a,17a-methylenedioxypregnene compounds of Formula 1.
As already stated above the various substitution and dehydrogenation reactions described hereinbefore for the conversion of compounds of Formula 1 to other compounds of this formula usually can also be applied to 14a,l7a-dihydroxypregnene derivatives of Formula 2. In some reactions it is preferred to protect the 2l-hydroxyl group, f.i. by esterification, before carrying out the substitution or dehydrogenation reaction.
The following examples further illustrate the best mode currently contemplated for carrying out the present invention but must not be construed as limiting the scope thereof in any manner whatsoever.
EXAMPLE 1 A mixture of 5.0 g. of l4a-hydroxy-hydrocortisone 2l-acetate, 5 ml. of paraldehyde, 1.3 ml. of perchloric acid (70% 3 ml. of water and 30 ml. of purified dioxane was kept for 46 hours at room temperature. To the reaction mixture 500 ml. of methyl isobutyl ketone were added and the resulting solution was successively washed with mmole of a solution of potassium carbonate in water and subsequently three times with 50 ml. of water. The solvent was completely removed by distillation under reduced pressure. The residue was crystallized from methanol, yielding 3.2 g. of 115,21-dihydroxy 14a,l7a-ethylidenedioxy-4-pregnene-3,20-dione ZI-acetate. Recrystallization from ethyl acetate/heptane gave a pure product.
Melting point: 183 C.; [a] '=+19O (c.=0.5;in CHCI A (in GHgOH) =242 m E}",?,,, =381 LR. (in CHCl u =361O, 1745, 173 0, 1663, 1615,
1138 and 1110 cm.-
N.M.R. (in CDCl 6:1.11, 1.30 (doublet), 1,42, 2.15,
4.47, 4.84, 5.13 (quadruplet), 5.67 p.p.m.
Elementary analysis.Calculated for C25H34O7 (percent): C, 67.26; H, 7.62. Found (percent): C, 67.56 and 67.59; H, 7.83 and 7.77.
EXAMPLE 2 In an analogous way to the procedure described in Example l, 14a-hydroxy-hydrocortisone 21-acetate was converted with cyclopropyl formaldehyde to 115,21-dihydroxy-14a,17ot-cyclopropylmethylenedioxy 4 pregnene- 3,20-dione 21-acetate.
Melting point: -135 c.; a ,,==+146 (c.=0.5; in
CHCI3) 7 LR. (in CHC13) r,,,,,=3612, 1745, 1730, 1660, 1615,
1130, 1102, 1012 cm.- N.M.R. (in CDCl 6:0.3-06 (multiplet), 1.12, 1.44,
2.15, 4.50, 4.67 (doublet), 4.90, 5.72 p.p.m.
Elementary alzalysl's.-Calculated for C27H36O7 (percent): C, 68.64; H, 7.63. Found (percent): C, 68.75 and 68.71; H, 7.51 and 7.55.
EXAMPLE 3 In an analogous way to the procedure described in Example 1, 14a-hydroxy-hydrocortisone Zl-acetate was converted with propanal to 1lB,21-dihydroxy-14a,17apropylidenedioxy-4-pregnene-3,20-dione 2l-acetate Melting point: lll12 C.; [oz] :+173 (c. :0.5; in
CHCl
)unnx (in CH OH)=242 m {Z',,, =296 LR. (in CHCl r,,,,,=3610, 1743, 1729, 1662, 1612,
N.M.R. (in CDCl 6:0.92 (triplet), 1.12, 1.45, 2.16,
4.45, 4.86, 4.91 (triplet), 5.68 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 67.83; H, 7.83. Found (percent): C, 67.87 and 67.89; H, 8.00 and 8.00.
EXAMPLE 4 In an analogous way to the procedure described in Example 1, l4a-hydroxy-hydrocortisone 2l-acetate was converted with butanal to l15,2l-dihydroxy-l4oc,l7a-butylidenedioxy-4-pregnene-3,20-dione 2l-acetate.
Melting point: 95-101 C.; a] =+174 (c.=0.5; in
CHCI
)\mux (in OH OI-I) =242 mp; E},,, =336 I.R. (in CHCl :368, 1745, 1730, 1665, 1618,
N.M.R. (in CDCl :0.90 (triplet), 1.12, 1.43, 1.58,
2.16, 4.47, 4.83, 4.96 (triplet), 5.67 p.p.m.
Elementary anaIysl's.Calculated for C27H33O7 (percent): C, 68,35; H, 8.02. Found (percent): C, 68.45 and 68.52; H, 8.06 and 8.04.
EXAMPLE 5 In an analogous way to the procedure described in Example 1, 14a-hydroxy-hydrocortisone 21-acetate was converted with pentanal to llfl,2l-dihydroxy-l4a,17apentylidenedioxy-4-pregnene-3,20-dione 2l-acetate. Melting point: l06.5-l08 C.; [a] =+l56 (c.:0.5; in
CHCl
LR. (in CHCl v =3612, 1743, 1730, 1664, 1614,
N.M.R. (in CDCl 6:0.90 (triplet), 1.11, 1.43, 2.16, I
4.45, 4.84, 5.69 p.p.m.
Elementary analysis.Calculated for C23H4QC7 (percent): C, 68.85; H, 8.20. Found (percent): C, 68.61 and 68.63; H, 8.16 and 8.14.
EXAMPLE 6 A mixture of 7.2 g. of 14ot-hydroxy-hydrocortisone 21- acetate, 40 ml. of nonanal, 160 ml. of methylene chloride and 2 ml. of perchloric acid (70%) was stirred for 6 hours and refluxed. The reaction mixture was successively washed with solutions of sodium sulphite and of sodium carbonate in water and with water. The methylene chloride layer thus purified was evaporated to dryness and the residue was crystallized from diethyl ether. The precipitate consisting of 3.9 g. of the by-product 14-dehydro-hydrocortisone 21- acetate was filtered off. Upon evaporation of the filtrate the residue was crystallized from heptane. Thus 12 g. of nearly pure 1 15,21-dihydroxy-14a,l7a-nonylidenedioxy-4-pregnene-3,20-di0ne 2l-acetate was obtained. Recrystallization from ethanol yielded 0.60 g. of the pure product. Melting point: 158-161 C.; [a] =+165 (c.=0.5; in
CHCl
)u'nax LR. (in CHCl v =36l2, 1745, 1738, 1665, 1618, 1130 N.M.R. (in CDCl 5:0.88 (triplet), 1.12, 1.29, 1.44,
2.17, 4.50, 4.85, 4.96 (triplet), 5.70 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 70.59; H, 8.82. Found (percent): C, 70.56 and 70.51; H, 8.85 and 8.90.
EXAMPLE 7 A mixture of 5.0 g. of 14a-hydroxy-hydrocortisone 21- acetate, 5.0 ml. of dimetllylsulphoxide, 1.6 ml. of perchloric acid (70%) and 40 m1. of p-isopropylbenzaldehyde was stirred for 7 days at room temperature. The reaction mixture was diluted with 150 m1. of methylene chloride and was successively washed with solutions of sodium bisulphite and of sodium carbonate in water and with water. The organic layer was evaporated to dryness. The residue was subjected to column chromatography (silica gel, eluent benzene/ acetone 3:1). 0.50 g. of nearly pure 115,21-dihydroxy-l4a,17a-(p-isopropy1benzylidenedioxy) 4 pregnene-3,20-dione 21-acetate was obtained. Chromatography on aluminium oxide, activity III (eluent benzene/acetone 7:1) was applied. The fractions containing the appropriate derivative were evaporated to dryness and the residue was crystallized from a mixture of methylene chloride and petroleum ether (B.P. 4060 C.): 0.25 g. of pure product precipitated.
Melting point: l44146 C.; [a] :+157 (c.=0.5;
error.
IR. (in CHC13)1 36l0, 1742, 1729, 1662, 1614 cm.- N.M.R. (in CDCl 5:1.20, 1.27 (doublet), 1.46, 2.15,
4.50, 4.88, 5.67, 5.92, 7.31 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 72.00; H, 7.64. Found (percent): C, 71.91 and 71.89; H, 7.70 and 7.72.
EXAMPLE 8 A mixture of 8.0 g. of 14a-hydroxy-hydrocortisone 21- acetate, 24 g. of 3-(methoxycarbonyl)-propanal, 1.0 ml. of perchloric acid (70% and ml. of methylene chloride was kept for 3 days at room temperature. The reaction mixture was worked up as usual and the residue obtained was purified by chromatography (aluminium oxide, activity III, eluent benzene/ethyl acetate 2:1). 0.75 g. of 11B,21dihydroxy-l4a,17a-(3 methoxycarbonylpropylidenedioxy)-4-pregnene-3,20-dione ZI-acetate was isolated.
Melting point: 128-l31 C.; [a] =+17l (c.=0.5; in
CHCl
Amer (in CH OH) =242 m EFZ ZQS I.R. (in CHCl v =36l2, 1730, 1663, 1615, 1140, 1040 N.M.R. (in CDCl 5:1.13, 1.44, 2.18, 3.68, 4.50, 4.83,
5.04 (triplet), 5.68 p.p.m.
Elementary analysis.-Calculated for C H 0 (percent): C, 64.86; H, 7.34. Found (percent): C, 65.00 and 65.01; H, 7.35 and 7.34.
EXAMPLE 9 A mixture of 5.0 g. of l4ot-hydroxy-hydrocortisone 21- acetate, 10 ml. of cortonaldehyde, 0.25 ml. of perchloric acid (70%) and 70 ml. of dioxane was kept for 29 hours at room temperature. 250 ml. of methylisobutyl ketone were added. The solution was washed with 50 ml. of a molar potassium carbonate solution in water and with water till neutral. The organic layer was evaporated to Melting point: 130l33 C.; [oc] =+159 (c.'=0.5; in
CHCl 1 Am. (in OH OH)=242 m E}".? =313 LR. (in CHCl )1/ =3612, 3092, 1743, 1728, 1662, 1615,
N.M.R. (in CDClg) 5:1.12, 1.43, 1.59, 1.73 (doublet),
2.15, 4.45, 4.86, 5.0-6.0 (multiplet), 5.62 p.p.m.
Elementary analysis.-C'alculated for C H O (percent): C, 68.64; H, 7.63. Found (percent): C, 68.80 and 68.74; H, 7.78 and 7.70.
EXAMPLE 10 In an analogous Way to the procedure described in Example 9, l4a-hydroxy-hydrocortisone 21-acetate was converted with furfural to 115,21-dihydroxy 14zx,17oc(2'- furylmethylenedioxy)-4-pregnene-3,20-dione 21-acetate.
Melting point: 122-123 C.; [ot]n=+161 (c.=0.5; in
CHC1
A (OH OH) :21? and 242 m 163 290 and 275 IR. (in 01101, u ,,,=3612, 1743, 1729, 1660, 1613,
N.M.R. (in CD01 6:1.17, 1.45, 2.14, 4.52, 4.85, 5.64,
5.95, 6.40 and 7.34-7.47 (multiplet) p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 67.47; H, 6.83. Found (percent): C, 68.67 and 68.63; H, 6.71 and 6.74.
EXAMPLE 1 1 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 2l-acetate was converted with p-chlorobenzaldehyde to 1113,21-dihydroxy- 14a,17a (p-chlorobenzylidenedioxy) 4-pregnene-3,20- dione 21-acetate.
Melting point: 231-237 C.; [0t] =-|174 (c.=0.5; in
'OHCl Am (in CH OH) =220 and 242 m l; E}" ,=304 and 283 LR. (in CH'CI v =36l2, 1742, 1730, 1662, 1615,
N.M.R. (in CDCl 6:1.20, 1.46, 2.17, 4.48, 4.87, 5.68,
5.93, 7.37 p.p.m.
Elementary analysis.Calculated for C30H3507C1 (percent): C, 66.37; H, 6.47; CI, 6.53. 'Found (percent): C, 66.39 and 66.50; H, 6.60 and 6.58; Cl, 6.70 and 6.53.
EXAMPLE 12 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with p-methoxybenzaldehyde to 11 8,21-dihydroxy 1441,1711.-(p-methoxybenzylidenedioxy) 4-prcgnene 3,20-dione 21-acetate.
Melting point: 184.5197 C.; [a] '=-|174 (c.=0.5; in
OHCl
IJR. (in CHCl v ,,,,=3611, 2843, 1745, 1729, 1663,
1612, 1600, 1578, 1505, and 1130cm.-
N.M. R. (in CDCl 8:1.20, 1.46, 1.70, 2.15, 3.82, 4.50, 4.87, 5.64, 5.90, 6.92 and 7.32 (AB-spectrum) p.p.m.
10 Elementary analysls.--Calcu1ated for C H O (percent): C, 69.15; H, 7.06. Found (percent): C, 69.25 and 69.24; H, 7.21 and 7.26.
EXAMPLE 13 In an analogous way to the procedure described in Example 9, l4a-hydroxy hydrocortisone 21-acetate was converted with a-naphthaldehyde to 11,8,21-dihydroxy 14oz, 17a-(1'-naphthylmethylenedioxy) 4-pregnene-3,20-dione 21-acetate.
Melting point: 175180 C.; [a] =+132 (c.=0.5; in
CHCl
7mm (in CH OH) =223, 238, 242, 270, 280 and 290 m LR. (in CHCI v =3612, 1744, 1730, 1663, 1615,
N.M.R. (in CDCl 5:1.24, 1.45, 1.87, 2.12, 4.45, 4.8 and 4.9 (AB-spectrum) 5.62 and 7.1-8.1 (multiplet) p.p.m.
Elementary analysis.-Calculated for C d-1 0 (percent): C, 73.12; H, 6.81. Found (percent): C, 73.35 and 73.40; H, 6.94 and 6.99.
EXAMPLE 14 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with cyclohexylformaldehyde to 116,21-dihydroxy 14a,17a-(cyclohexylmethylenedioxy)-4-pregnene- 3,20-dione 21-acetate.
Melting point: 139-141 C.; [a]n='+l77 (c.=0.5; in
CHCl
A (in CH OH) =241 m E}'Z,,, =326 I.R. (in CHCl,) 1/ =3610, 1743, 1728, 1660, 1614,
N.M.R. (in CDC1 5:1.12, 1.44, 2.16, 4.43, 4.67, 4.83,
5.68 p.p.m.
Elementary analysis-Calculated for C H O (percent): C, 70.04; H, 8.17. Found (percent): C, 69.82 and 69.80; H, 8.28 and 8.32.
EXAMPLE 15 In an analogous way to the procedure described in Example 9, 14ahydroxy hydrocortisone 21-acetate was converted with 3-phenylpropanal to 1118,21-dihydroxy 14oz, 174x-(3'-phenylpropylidene dioxy) 4-pregnene-3,20-dione 21-acetate.
Melting point: 1131l6 C.; [oz] ==-|-142 (c .'=0.5; in
CHCl Amax HIM; LR. (in CHC13) v =3615, 1745, 1730, 1662, 1490,
N.M.R. (in CDCl;,) 6:1.12, 1.43, 2.17, 4.50, 4.82, 4.97
(triplet), 5.68, 7.22 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 71.64; H, 7.46. Found (percent): C, 71.69 and 71.63; H, 7.56 and 7.51.
EXAMPLE 1 6 In an analogous Way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with Z-thiophenealdehyde to 1113,21-dihydroxy 14a,17w(2-thienylmethylenedioxy) 4-pregnene-3,20-dione 21-acetate.
Melting point: 131-134 C.; [a] =+198 (c.=0.5; in
CHCI
A (in CH OH) =238 m E1Z =384 LR. (in CHCl 11 =3610, 1740, 1728, 1660, 1612 cm.- N.M. R. (in CD01 5:1.19, 1.45, 2.13, 4.5, 4.85, 5.60,
6.20, 7.3-7.5 (multiplet) p.p.m.
Elementary analysis.Calculated for C H O S (percent): C, 65.37; H, 6.61; S, 6.23. Found (percent): C, 65.46 and 65.50; H, 6.73 and 6.65; S, 6.21 and 6.21.
EXAMPLE 17 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with isovaleraldehyde to 11B,21-dihydroxy-14a, 17cc (3' methylbutylidenedioxy)-4-pregnene-3,20-dione 2l-acetate.
Melting point: 148149 C.; [a] =+179 (c.=0.5; in
CHC1
A (in CH OH)=242 mu; E1t...=295 LR. (in CHCI v =36l2, 1743, 1728, 1665, 1615,
1370, 1128 Cm. N.M.R. (in CDCl 6:0.91 (doublet), 1.10, 1.43, 2.17,
4.48, 4.83, 5.01 (triplet), 5.67 p.p.m.
Elementary analysis.-Calculatcd for C23H40O7 (percent): C, 68.85; H, 8.20. Found (percent): C, 68.90 and 68.84; H, 8.26 and 8.24.
EXAMPLE 18 In an analogous way to the procedure described in Example 9, 14a-hydroxy-hydrocortisone 21-acetate was converted with benzaldehyde to 11/3,21-dihydroxy-14a,17abenzylidenedioxy-4-pregnene-3,20-dione 21-acetate.
Melting point: 186189 C.; [a] =+170 (C.=0.5; in
CHC1
Mm (in CH OH)=240 mu; E}? =810 I.R. (in CHC1 v,,,,,=3612, 1745, 1732, 1663, 1617,
N.M.R. (in CDC1 )6=1.21, 1.48, 2.14, ca. 4.5, 4.91, 5.62,
5.93, 7.35-7.45 (multiplet) p.p.m.
Elementary analysis.Calculated for C H O (perent): C, 70,87; H, 7.09. Found (percent): C, 70.92 and 70.96; H, 7.10 and 7.15.
EXAMPLE 19 A solution of 22.0 g. of l1B,21-dihydroxy-14u,17oethylidenedioxy 4 pregne'ne-3,20-dione 21-acetate prepared according to the process of Example 1 and 14.3 g. of 2,3-dichloro 5,6-dicyanobenzoquinone in 200 m1. of dioxane was stirred at 95 C. After 1.5 h. the precipitate formed; 12.9 g. of the benzoquinone, was filtered off and was thoroughly washed with methylene chloride. The filtrate was stirred for 30 min. with 40 g. of aluminum oxide that had been acidified (30 ml. of acetic acid (10%)/kg. aluminum oxide. The aluminum oxide was filtered 011" and the filtrate was again stirred with 40 g. of acidified aluminium oxide. This procedure was repeated 5 times, during the last of which 6 g. of charcoal was added. A solution of the steroid, thus purified, in methylene chloride and dioxane was evaporated to dryness. The residue was crystallized from diethyl ether. 14.4 g. of 11p,2l-dihydroxy-l4a,17a ethylidenedioxy 1,4- pregnadiene-3,20-dione 21-acetate precipitated, which was recrystallized from a mixture of 200 ml. of methyl isobutylketone and 100 ml. of heptane, yielding 10.5 g. of pure 1 1B,21-dihydroxy-14a,Hot-ethylidenedioxy-1,4-pregnadiene-3,20-dione 21-acetate.
Melting point: 115119 C.; [a] =+146 (C.=0.5; in
in CHCl am... (in 011,011) =242 m 131%?288 I.R. (in 01101, V,,,,,,=3610, 1745, 1730, 1658, 1622, 1602, 1109 cm. N.M.R. (in CDCl 6:1.16, 1.28
(doublet), 1.47, 2.16, 4.5, 4.88, 5.17 (quadruplet), 6.04, ca. 6.32 and ca. 7.41 (multiplets) p.p.m.
Elementary analysis.-Calculated for C H O (percent): C, 67.57%; H, 7.21%. Found (percent): C. 67.59 and 67.55%; H, 7.24 and 7.18.
12 EXAMPLE 20 A suspension of 2.0 g. of 11/3,21-dihydroxy-14a,17oethylidenedioxy-4-pregnene-3,20-dione 21-acetate prepared according to the process of Example 1, 6.0 g. of chloranil and 140 ml. of tert. butanol was stirred and refluxed for 1.5 h. The reaction mixture was then stirred for 15 hours at room temperature and was filtered. The filtrate was evaporated to dryness and the residue was purified by column chromatography, adsorbent: aluminum oxide, activity III, eluent: 4% acetone in benzene. After evaporation to dryness of the appropriate fractions the residue crystallized from diethyl ether, yield: 0.56 g. of 116,21-dihydroxy-14a,l7a-ethylidenedioxy-4,6- pregnadiene-3,20-dione ZI-acetate.
Melting point: 204205 C., [a] =+22l (c.=0.5; in
CHCl
A (in CH OH)=282 m E1Z nn 570 LR. (in CHCl )1/ :3610, 1740,1728,1650,1618, 1580,
N.M.R. (in CDCl )6=1.17, 1.30 (doublet), 1.37, 2.18,
4.48, 4.85, 5.20 (quadruplet), 5.63, 6.15 p.p.m.
Elementary analysis.-Calculated for C H O (percent): C, 67.87; H, 6.79. Found (percent): C, 67.62 and 67.51; H, 7.28 and 7.22.
EXAMPLE 21 In a similar way to the procedure described in Example 19, 11B,21-dihydroxy-14u,17u-ethy1idenedioxy-1,4,6- pregnatriene-3,20-dione ZI-acetate was obtained from 116, 21 dihydroxy 14a,17a-ethylidenedioxy-4,6-pregnadiene- 3,20-dione 21-acetate (prepared according to the process of Example 20) by reaction with 2,3-dichloro-5,6- dicyanobenzoquinone.
Melting point: 196188 C.; [a] =+154 (c.=0.5);
in CHCl A... (in CH OH)=220, 254 and 298 m E}Z',,,,=298
222 and 287 LR. (in CHC1 )1 :3610, 1740, 1728, 1648, 1627, 1600,
N.M.R. (in CDCl )6=1.18, 1.25 (doublet), 1.43, 2.17, 4.52, 4.85, 5.18 (quadruplet), 5.95-6.40 (multiplets) p.p.m. Elementary analysis.Ca1culated for C H O (percent: C, 67.87; H, 6.79. Found (percent): C, 67.62 and 67.58; H, 6.83 and 6.88.
EXAMPLE 22 (A) A solution of 4.3 g. of llfi,2l-dihydroxy-l4a,l7uethylidenedioxy-1,4-pregnadiene-3,2O dione 21 acetate prepared according to the process of Example 19 in 30 ml. of tetrahydrofuran and 22 m1. of pyridine was cooled down to -10 C. With stirring and continued cooling 2.9 ml. of thionyl chloride were cautiously added drop- Wise. The ensuing suspension was rapidly brought to 0 C. After 15 minutes the reaction mixture was poured into 600 ml. of water, to which 5 g. of sodium chloride had been added. 4.0 g. of amorphous 21-hydroxy-14a- 17oz ethylidenedioxy 1,4,9(11)-pregnatriene-3,20-dione 21-acetate were obtained.
A (in CH OH) =239 mu; ElZ =350 LR. (in CHCl )1/ =1749, 1732, 1665, 1625, 1609, 1409,
(B) A solution of 1.0 g. of the compound thus obtained and 0.5 ml. of perchloric acid (0.68 N) in 10 ml. of dioxane was treated with 0.62 g. of dibromantine. This reaction mixture was stirred for 2.5 hours in the dark at room temperature and was then poured into a solution of 1.7 g. of sodium pyrosulphite in ml. of water. 1.2 g. of a solid precipitated which, upon crystallization from methanol, yielded 0.2 g. of pure 115,21-
dihydroxy 9a brom-l4a,17a-ethylidenedioxy-1,4-pregnadiene-3,20-dione 21-acetate.
Melting point: 172l73 C. (decomposition); M
-|-162 (C. -0.5; in OHCig) Amax (in Ill/l;
I.R. (in CHCl l/ '=36O8, 1745, 1731, 1662, 1122-1112 N.M.R. (in CDCl )6=1.16, 1.37 (doublet), 1.74, 2.17, 3.4, 4.92, 5.22 (quadruplet), 6.05, 6.30 (doublet), 7.53 (doublet) p.p.m.
Elementary analysis.-Calculated for C25H3107BI' (percent): C, 57.36; H, 5.93; Br, 15.30. Found (percent): C, 57.26 and 57.29; H, 5.82 and 5.79; Br, 15.19 and 15.22%.
EXAMPLE 23 To an ice-cooled solution of 5.5 g. of 21-hydroxy-14a, 17a ethylidenedioxy 1,4,9(l1)-pregnatriene-3,20-dione 21-acetate prepared according to the process of Example 22A and 22 g. of lithium chloride in 220 ml. of acetic acid 1.9 g. of N-chlorosuccinimide and 3.9 ml. of a 4 N solution of hydrochloric acid in dioxane were successively added. The reaction mixture was stirred for an additional hour at 0 C. and was poured into 1.75 l of water. The solid precipitated was crystallized from a mixture of methanol/ water. 2.9 of crystalline material thus obtained were purified by chromatography on a column of 150 g. of silica gel, eluent diethyl ether in benzene. Upon evaporation to dryness of the appropriate fractions a residue was obtained which crystallized from diethyl ether; yield 1.0 g. of 21-hyd-roxy-14a,l7a-ethylidenedioxy- 9a,11fl-dichloro 1,4-pregnadiene-3,20-dione 21-acetate.
Melting point: 195196.5 C.; [a] |-223 (c.=0'.5;
in CHCl Am (in CH OH) =238 my, shoulder at. 265 m Elfi 295 and 100 IR. (in CHCl )v =1743, 1730, 1665, 1625, 1608, 1402,
N.M.R. (in CDCl )6=1.23, 1.37 (doublet), 1.71, 2.19, 3.3-3.7 (multiplet), 4.87, 5.11 (quadruplet), 6.09, 6.40 and 7.40 (AB-quartet) p.p.m.
Elementary analysis.Calculated for C H O Cl (percent): C, 60.36; H, 6.04; Cl, 14.28. Found (percent): C, 60.11 and 60.08; H, 6.16 and 6.20; CI, 14.39 and 14.37.
EXAMPLE 24 A nitrogen-flushed solution of 15.6 g. of 1119,21-dihydroxy-14a,17a-ethylidenedioxy-4-pregnene 3,20 dione 21-acetate prepared according to the process of Example 1 in a mixture of 125 ml. of methylene chloride and 125 ml. of methanol was treated with 1.4 ml. of 1.0 N sodium methoxide in methanol. The reaction mixture was left standing for 45 min. at room temperature, was then neutralized with 0.2 ml. of acetic acid and evaporated to dryness. The residue was crystallized from methanol to yield 9.4 g. of 11B,21-dihydroxy-14a,17aethylidene-dioxy-4-pregnene 3,20 dione. From the mother liquid, 1.7 g. of this compound was isolated.
Melting point: 251-253 C.; [a] =|22O (c.'=0.5; in
CHCI
Am (in OHgOH) (percent) 242 m E}"{,",,, =404 LR. (in CHCl 'y ,,,,-=3616, 3500, 1713, 1665, 1619,
N.M. R. (in CDCl 6:1.15, 1.31 (doublet), 1.43, ca.
3.1 (disappears after washing with D 0), 4.4 (broad), 5.20 (quadruplet), 5.70 p.p.m.
Elementary analysis.-Calculated for C l-1 0 (percent): C, 68.31; H, 7.92. Found (percent): C, 68.24 and 68.26; H, 7.93 and 7.94.
14 EXAMPLE 25 In an analogous way to the procedure described in Example 24, 11fi,21dihydIOXy14a,17a butylidenedioxy- 4-pregnene-3,20-dione 21-acetate prepared according to the process of Example 4 was converted to llfl-Zl-dihydroxy-14a,17a-butylidenedioxy-4-pregnene-3,20-di0ne.
Melting point: 94.5-97 C.; [a] =|l c.=0.5; in
CHCl
LR. (in 'CHCI 7 =36l5, 3500, 1711, 1665, 1615,
N.M.R. (in CDCl 6:0.93 (triplet), 1.16,, 1.49, 4.18, and 4.68 (AB-quartet), 4.48, 5.00 (triplet), 5.72 p.p.m.
Elementary analysis.--Calculated for C H O (percent): C, 69.44; H, 8.33. Found (percent): C, 69.29 and 69.25; H, 8.33 and 8.35.
EXAMPLE 26 In an analogous way to the procedure described in Example 24, 1113,21-dihydroxy 14a,l7a-ethylidenedioxy- 1,4-pregnadiene-3,20-dione 21-acetate, prepared according to the process of Example 19 was converted to 1113,21- dihydroxy-l4a,l7a-ethylidenedioxy 1,4 pregnadiene- 3,20-dione.
Melting point: 209212 C.; [a] =+l7l (C.=O.5; in
CHCI
I.R. (in CHCl v =3613, 3500, 1714, 1663, 1622,
N.M.R. (in CDCl;,) 5:1.18, 1.29 (doublet), 1.47, 4.15 and 4.60 (AB-quartet), 4.5, 5.13 (quadruplet), 6.03, 6.28 and 7.37 (AB-quartet) p.p.m.
Elementary analysis.-Calculated for C H O (percent): C, 68.66; H, 7.46. Found (percent): C, 68.53 and 68.60; H, 7.56 and 7.62.
EXAMPLE 27 In an analogous way to the procedure described in Example 24, 1lB,21-dihydroxy-14a,17a-(Z-furylmethylenedioxy)-4-pregnene-3,20-dione was obtained from 115,21- dihydroxy-14a,17a-(2-furylrnethy1enedioxy) 4 pregnene-3,20-dione 21-acetate prepared according to the process of Example 10.
This compound was isolated as an oil. [a] =+181 (c.=0.5; in CHCl A (in CH OH) =217 and 242 m E}Z,,,,=330 and 320 IR. (in 01101, V ,,,=3612, 3500, 1712, 1660, 1612, 750
N.M.R. (in CDC1 6:1.17, 1.45, 4.17 and 4.62 (AB- quartet), 4.52, 5.64, 5.94, 6.40, 7.3-7.5 (multiplet) p.p.m.
Elementary analysis.-Calculated for C H O (percent): C, 68.42; H, 7.02. Found (percent): C, 68.19 and 68.22; H, 6.85 and 6.91.
EXAMPLE 28 Elementary analysis.Calculated for C H O- (percent): C, 69.32; H, 8.37. Found (percent): C, 69.17 and 69.22; H, 8.33 and 8.39.
EXAMPLE 29 In an analogous way to the procedure described in Example 28, 11B,21-dihydroxy-14a,17ot butylidenedioxy- 4-pregnene-3,20-dione 2l-(1'-adamanty1)carboxylate was prepared from 115,21-dihydroxy-14a,l7a-butylidenedioxy-4-pregnene-3,20-dione prepared according to the process of Example by reaction with l-adamantylcarbonyl chloride.
Melting point: 276277 C.; [a] =+177 (c.=0.5;
in CHCl Am... (in GI-I3OH)=242 Inn; 12 :289
1cm. LR. (1111 CHCl 11 =36l0, 1720, 1662, 1617, 1110 cmr N.M.R. (in CDCl 6:0.92 (triplet), 1.10, 1.42, 1.73,
1.97, 4.48, 4.83, 4.95 (triplet), 5.67 p.p.m. Elementary analysis.-Calculated for C H O (percent): C, 72.73; H, 8.42. Found (percent): C, 72.65 and 72.69; H, 8.49 and 8.53.
EXAMPLE In an analogous way to the procedure described in Example 28, 11fi,21-dihydroxy-14a,17a butylidenedioxy 4-pregnene-3,20- dione 21-(3'-phenyl)propionate was prepared from 115,2l-dihydroxy-14a,17a-butylidenedioxy-4- pregnane-3,20-dione prepared according to the process of Example 25 by reaction with 3-phenylpropionyl chloride. Melting point: 163-166 C.; [a] =+167 (c.=0.5;
in CHCl Am... (in OH3OH) :242 my; E}'Z,,. =266 I.R. (in CHC13) v ,,,,=3612, 1728, 1664, 1615, 1160,
1153,1128,1112 Ont- N.M.R. (in CDCl 6:0.93 (triplet), 1.13, 1.44, 4.50,
4.88, 4.98 (triplet) 5.69.
Elementary analysis.Calculated for C H O (percent): C, 72.34; H, 7.80. Found (percent): C, 72.04 and 72.07; H, 7.89 and 7.90.
EXAMPLE 31 In an analogous way to the procedure described in Example 28, 1lfl,21-dihydroxy 14a,17ot-butylidenedioxy-4- pregnene-3,20-dione 21-decanoate was prepared from 115, 21-dihydroxy-l4a,17a butylidenedioxy 4 pregnene- 3,20-dione prepared according to the process of Example 25 by reaction with nonylcarbonyl chloride.
Melting point: 148150 C.; [e] =+167 (c.=0.5; in
CHCIg) 1 (in 011,011) :242 mp; E:% ,=2'65 LR. (in CHC1 v 36l0, 1740, 1725, 1660, 1614,
1110 cm.- N.M.R. (in CDCl 6=0.8-1.0 (multiplet), 1.12, 1.30,
1.43, 4.48, 4.86, 4.98 (triplet), 5.69 p.p.m. Elementary analysis. Calculated for C H O (percent): C, 71.67; H, 9.22. Found (percent): C, 71.51 and 71.55; H, 9.21 and 9.29.
EXAMPLE 32 In an analogous way to the procedure described in Example 28, ll{1,2l-dihydroxy-14a,l7a-butylidenedioxy- 4-pregnene-3,20-dione 2l-pivalate was prepared from 115,
1 6 2l-dihydroxy-14a,17a-butylidenedioxy 4-pregnene-3,20-dione prepared according to the process of Example 25 by reaction with pivalolyl chloride.
Melting point: 175177 C.; [a] :+18l (c.=0.5; in
CHCl
A (in CH OH) =242 m E}Z1,, =293 LR. (in CHCl )1/ =3612, 1735, 1723, 1663, 1 615,
1158, 1125, 1110 cm. N.M.R. (in CDCl )6=O.93 (triplet), 1.13, 1.27, 1.45,
4.50, 4.85, 4.98 (triplet), 5.69 p.p.m.
Elementary analysis-Calculated for C H O (percent): C, 69.77; H, 8.53. Found (percent): C, 69,53 and 69.57; H, 8.50 and 8.51.
EXAMPLE 33 In an analogous way to the procedure described in Example 28, 116,21-dihydroxy-14u,l7a-butylidenedioxy- 4-pregnene-3,20-dione 2l-isonicotinate was prepared from 116,21 dihydroxy 14a,17u-butylidenedioxy-4-pregnene- 3,20-dione prepared according to the process of Example 25 by reaction with isonicotinic acid anhydride.
Melting point: 156158 C.; [a] :+219 (c.=0.5; in
CHC1
k (in CH OH)=242 and 285 shoulder) m E}"' 349 and 50 LR. (in CHCl )u =36]2, 1740, 1726, 1660, 1615,
N.M.R. (in CDCl )5=0.93 (triplet), 1.17, 1.47, 4.51, 5.02
(triplet), 5.15, 5.68, 7.88 and 8.80 (AB-spectrum) Elementary analysis.--Calculated for C H O N (percent): C, 69.27; H, 7.26; N, 2.61. Found (percent): C, 69.39 and 69.23; H, 7.37 and 7.35; N, 2.61 and 2.62.
EXAMPLE 34 (A) According to the process described in Example 1, 14a,17ot,21 trihydroxy-4-pregnene-3,20-dione 21-acetate was converted with paraldehyde to 21-hydroxy-14a,17aethylidenedioxy-4-pregnene-3,20-dione 21-acetate.
Melting point: 177179 C.; [a] =+l77 (c.=0.5; in
CHCl
I.R. (in CHCl )1 =1747, 1730, 1665, 1612, 1112,
N.M.R. (in CDCl )5=0.88, 1.19, 1.37 (doublet), 2.17,
4.90, 5.15 (quadruplet), 5.75 ppm.
Elementary analysis.Calculated for C H O (percent): C, 69.77; H, 7.91. Found (percent): C, 69.49 and 69.53; H, 7.89 and 7.88.
(B) According to the process described in Example 24, the compound thus obtained was converted to 21-hydroxy- 14a,17tx-ethylidenedioxy-4-pregnene-3,20-dione.
Melting point: 211-2l5 C.; [a] :+l58 (c.=0.5; in
CHCl
LR. (in cHc1,)u ,,.=3505, 1715, 1668, 1618, 1113,
N.M.R. (in CDCl )6=0.89, 1.17, 1.35 (doublet), 3.13
(triplet), 4.4, 5.17 (quadruplet), 5.75 ppm.
Elementary analysis.-Calculated for C H O (percent): C, 71.10; H, 8.30. Found (percent): C, 70.89 and 70.83; H, 8.29 and 8.34.
(C) Ten liters of a nutrient medium consisting of 0.5% of glucose and 0.5% of corn steep liquid were inoculated with 500 ml. of a shake culture of Curvnlaria lnnata.
The micro-organism was grown at 26 C. with vigorus shaking and aeration. After 24 h. a solution of 3 g. of 21 hydroxy-14a,17ot-ethylidenedioxy-4-pregnene-3,20-dione prepared according to the above process in ml. of dimethyl formamide was added. Within 48 h. the conversion was complete. The mycelium was filtered off and washed with water. The filtrate and the washing were combined and thrice extracted with 2 l. of methyl isobutyl 17 ketone. The extract was evaporated to dryness under reduced pressure, the residue was crystallized from methanol/water.
1.4 g. of 11B,21-dihydroxy 14a,17ot-ethylidenedioxy-4- pregnene-3,20-dione was obtained.
Melting point: 25l253 C.; [a] =+218 (c.=0.5; in
CHCl
A (in CH OH) :242 my; E}% =4.00 I.R. (in CHCl )1 =3616, 3500, 1713, 1665, 1619,
N.M.R. (in CDCl )6=1.15, 1.31 (doublet), 1.43, 3.1 (disappears after washing with D 4.4, 5.20, 5.70 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 68.31; H, 7.92. Found (percent): C, 68.29 and 68.28; H, 7.90 and 7.94.
EXAMPLE 35 (A) In an analogous way to the procedure described in Example 34C, 21 hydroxy 140:,170: ethylidenedioxy-4- pregnene-3,20-dione prepared according to the processes of Examples 34A and B was converted with Aspergillus ochraceus to 11all-dihydroxy-14a,17a-ethylidenedioxy- 4-pregnene-3,20-dione.
Melting point: 2l0214 C.; [a] =+159 (c.'=0.5; in
CHCl
7m (in OH OH) :242 mp, E}'' =393 LR. (in CHCl )1/ =3600, 3490, 1712, 1662, 1612,
1402, 1110, 1090 cm.- N.M.R. (in CDCl )5=0.91, 1.31, 2.62 (doublet), ca. 4.1,
ca. 4.3, and 4.5 (AB-quartet), 5.18 (quadruplet), 5.74
p.p.m.
Elementary analysis.-Calculated for C H O (percent): C, 68.13; H, 7.92. Found (percent): C, 68.20 and 68.18; H, 7.92 and 7.94.
According to the process described in Example 28 the compound thus obtained was converted with acetic anhydride to 1101,21 dihydroxy 1411,17 a ethylidenedioxy4- pregnene-3,20-dione 21-acetate.
(B) 12 g. of 1111,2l-dihydroxy-14a,17a-ethylidenedioxy-4-pregnene-3,20-dione Zl-acetae prepared according to the above process were stirred in a solution of 4 g. of CrO in 140 ml. of acetic acid and 40 ml. of water. The conversion was complete within 10 minutes (thin layer chromatography) After minutes a solution of 12 g. of sodium hydrogen sulphite in 120 ml. of water was added to decompose the excess of reagent. The reaction mixture was diluted with water and extracted with methyl isobutylketone. The extract was washed with an aqueous hydrogen carbonate solution and water and evaporated to dryness in vacuo. The residue Was taken up in a little benzene and separated on a silica gel column (700 g. of silica gel; eluentzbenzene/ acetone 11:1). The fractions containing the product were combined and evaporated to dryness in vacuo. The residue was crystallized from methyl isobutylketone; yield: 5.2 g. of 21 hydroxy-14a,17a-ethylidenedioxy-4-pregnene-3,11, ZO-trione 21-acetate.
Melting point: 243-245 C.; [a] =+252 (c.=0.5; in
CHC13) k (in OH OH) :237 mn; El"'m =357 LR. (in CHCl )1/ =1745, 1730, 1705, 1664, 1615,
1406, 1372, 1109 cm. N.M.R. (in CDCl )5=0.84, 1.40, 1.45 (doublet), 3.29-
3.51 (AB-spectrum), 4.81-4.83 (AB-spectrum), 5.31 (multiplet), 5.73 p.p.m. Elementary analysis.Calculated for C H O (percent): C, 67.57; H, 7.21. Found (percent): C, 67.34 and 67.29; H, 7.35 and 7.33.
EXAMPLE 36 A solution of 4 g. of 21-hydroxy 14a,17a-ethylidenedioxy-4-pregnene-3,11,20-trione 21-acetate prepared according to the processes of Example 35 in 40 ml. of methylene chloride was saturated with nitrogen for 30 minutes. 1 ml. of 1 N solution of sodium methoxide in methanol was added and the mixture was stirred at room temperature in a nitrogen atmosphere. The conversion was complete within 20 minutes (thin layer chromatography). The mixture was neutralized and evaporated to dryness. After crystallization from methyl isobutyl ketone/diethyl ether the residue yielded 2.2 g. of 2l-hydroxy-14a,17x-ethy1idenedioxy-4-pregnene-3,11,20-trione. Repeated crystallization from methanol and from diethyl ether aiforded a product melting at 205208 C.; [a] +345 (c.=0.5; in CHCI )\max (in. mil;
I.R. (in CHCl )v =348O, 1708, 1665, 1616, 1405, 1111 cm.- N.M.R. (in CDCl )6=0.94, 1.39, 1.44 (doublet), 3.28-
3.48 (AB-spectrum), 4.31-4.45 (AB-spectrum, 5.32
(multiplet), 5.73 p.p.m.
Elementary analysis.Calculated for C H O (percent): C, 68.66; H, 7.46. Found (percent): C, 68.55 and 68.50; H, 7.47 and 7.44.
The invention includes within its scope pharmaceutical preparations containing, as the active ingredient, at least one of the therapeutically active compounds of the general formula according to fig. 1 in association with a pharmaceutically acceptable carrier. The preparations may take any of the forms customarily employed for administration of therapeutically active substances, but the preferred types are those suitable for oral administartion, especially tablets, including sustained release tablets, pills and capsules including the substance, those suitable for parenteral administration and those for local application.
The tablets and pills may be formulated in the usual manner with one or more pharmaceutically acceptable diluents or excipients, and include materials of lubricating nature. Capsules made of absorbable material, such as gelatin, may contain the active substance alone or in admixture, with a solid or liquid diluent. Liquid preparations may be in the form of suspensions, emulsions, syrups, or elixirs of the active substance in water or other liquid medium commonly used for making orally acceptable pharmaceutical formulations. The active substance may also be made up in a form suitable for parenteral administration, i.e. as a suspension or emulsion in sterile water or an organic liquid usually employed for injectable preparations, for example a vegetable oil such as corn or olive oil, or a sterile solution in water or an organic solvent.
The active substance may also be made up in creams, ointments and lotions suitable for local application. These preparations may be formulated in the usual manner with one or more pharmaceutically acceptable diluents or excipients. The preparation of a suitable cream for local application is described in the following example.
EXAMPLE 37 Ingredients:
113,21 dihydroxy 14a,17a-butylidenedioxy-4-pregnene-3,20-dione 21-isonicotinate-25 mg. Lanette 0-7.2 g. Cetomacrogol 1001.8 g. Paraffin liq.-6.0 g. Vaseline15.0 g. p-Chloro-m-cresol0.1 g. Sodium benzoate--0.l g. Citric acid (anhydrous)0.25 g. Sodium citrate-0.4 g. Water, ad 100.0 g.
PREPARATION A mixture of lanette 0, cetomacrogol 1000 (=polyethylene glycol 1000 monocetyl ether), parafiin liq. and vaseline was stirred at C. until homogeneous. Then the citric acid the sodium citrate and the sodium benzoate were dissolved in 68 ml. of Water. Of 1 ml. of this solution the pH was established (should be about and this ml. solution was set apart. The p-chloro-m-cresol was added to the aqueous solution and the mixture was heated to about 70 C. Then while stirring was continued vigorously the first mixture was added (if desired through a filter cloth). The cream thus obtained was cooled while stirring was continued to room temperature.
The steroid (particle size below lO t) was brought in suspension in the 1 ml. aqueous solution that was set apart and this mixture was added to the cream obtained. The mixture was homogenized during 30 minutes in a homogenizor.
When used for local application the concentration of the active compound of Formula 1 in the creams, ointments and lotions may vary between 0.01% and 1%. For oral use, in the form of tablets for example, each tablet may contain from 0.25 mg. to 25 mg. of the active substance. Suitable daily dosages to humans consist of 1 to 4 tablets. When used for parenteral administration, for example suspensions for intramuscular administration or solutions for intravenous administration concentrations may vary from 5 to 25 mg./ml., while the daily dosage in human application will vary from 1 to 2 ml.
For use in the veterinary field the concentration of the active substance in injectable preparations (suspensions as well as solutions) may vary from 0.1 to ing/ml. Daily dosages 1 to 2 ml. for dogs and cats 1 to 3 ml. for pigs 10 to ml. for cows and horses.
CHRl
in which the dotted lines in positions 1-2 and 67 indicate the optional presence of another bond, and wherein R represents (a) a straight or branched chain aliphatic hydrocarbon group, which group has less than 9 carbon atoms and may be substituted by a loweralkoxycarbonyl group,
(b) a phenyl group which phenyl group has less than 11 carbon atoms and may be substituted in the para position by a halogen atom, a loweralkyl, and a lower-alkoxy group or the naphthyl (c) an aryl-loWer-alkyl group,
((1) a cycloalkyl group having 3 to 6 carbon atoms,
(e) the furyl group, or
(f) the thienyl group;
R represents an tat-hydrogen atom or an ot-halogen atom;
R represents (a) an a-hydrogen atom together with a fl-hydroxyl group or a B-halogen atom or (b) an oxo group, and
R represents a hydrogen atom or an acyl group of an organic carboxylic acid.
2. 14a,17a-methylenedioxypregnane derivative according to claim 1, wherein R represents a straight or branched chain alkyl group of less than 5 carbon atoms.
3. 14a,l7a-methylenedioxypregnane derivative according to claim 1 wherein R represents a methyl, ethyl, propyl, butyl, Z-methylpropyl or propenyl group.
4. 14a,17a-methylenedioxypregnane derivative according to claim 1, wherein R represents an tat-hydrogen atom and a fl-hydroxyl group.
5. 14a,17ot-methylenedioxypregnane derivative according to claim 1, wherein R represents a hydrogen atom.
6. 14a,l7a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,2l-dihydroxy- 14a,17ot-ethylidenedioxy-4-pregnene-3,20-dione.
7. 14a,l7a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 14a,l7a-ethylidenedioxy-4-pregnene-3,20-dione 21 acetate.
8. 14a,17vt-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,6,2l-dihydroxy- 14a, Hot-ethylidenedioxy-1,4-pregnadiene-3,20-dione.
9. 14a,l7ot-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,2l-dihydroxy- 14m,l7ot-ethylidenedioxy-1,4-pregnadiene-3,20 dione-21- acetate.
10. l4a,17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,21-dihydroxy- 14a,17a-ethylidenedioxy-4,6 pregnadiene 3,20 dione 2l-acetate.
11. 14a,l7a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 14a,l7a-ethylidenedioxy-1,4,6-pregnatriene 3,20 dione ZI-acetate.
12. 14a,l7a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy 9a-bromo l4oc,l7ot ethylidenedioxy 1,4 pregnadiene- 3,20-dione 21-acetate.
13. 14a,17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,2l-dihydroxy- 14a,l7a-propylidenedioxy-4-pregnene-3,20 dione 21-acetate.
14. 14a,17a-methylenedioxypregnane derivative accord ing to claim 1 in which the derivative is llfi,2l-dihydroxy 14a,17a-butylidenedioxy-4-pregnene-3,ZO-dione.
15. 14a,17ot-methylenedioxypregnane derivative according to claim 1 in which the derivative is 1113,2l-dihydroxy- 14a,17a-butylidenedioxy-4-pregnene 3,20 dione 21-acetate.
16. 14a,l7u-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11B,21-dihydroxyl4u,l7et-butylidenedioxy 4 pregnene 3,20 dione 21- butyrate.
17. 14a,l7u-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11fl,21-dihydroxy- 14a,17u-butylidenedioxy-4-pregnene-3,20 dione 21 (l adamantyl) carboxylate.
18. 14a,17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 14oz,17ot-butylidenedioxy-4-pregnene-3,20 dione 21 (3'- phenyl)propionate.
19. 14a,17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11fi,21-dihydroxy- 14oz,17a-butylidenedioxy-4-pregnene 3,20 dione 21- decanoate.
20. 14a,17u-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,2l-dihydroxy- 14a,17a-butylidenedioxy 4 pregnene 3,20 dione 21- pivalate.
21. 14a,l7a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 14a,17ot-butylidenedioxy 4 pregnene 3,20 dione 21- isonicotinate.
22. 14a17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 14a,17a-pentylidenedioxy 4 pregnene 3,20 dione 21- acetate.
23. 14a,17a-metbylenedioxypregnane derivative according to claim 1 in which the derivative is 1113,21-dihydroxy- 14a,l7a-(Z'butenylidenedioxy)-4-pregnene-3,20-dione 21- acetate.
24. 14a,17ot-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydrxy- 14a,17w(3'methylbutylidenedioxy) 4 pregnene 3,20- dione ZI-acetate.
25. 14a,17a-methylenedioxypregnane derivative according to claim 1 in which the derivative is 1113,21-dihydroxy- 14a,17ot-benzylidenedioXy-4-pregnene 3,20 dione 21- acetate.
26. 14a,17u-methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,21-dihydroxy- 14cc,171x-(p-chlorobenzylidenedioxy) 4 pregnene-3,20 dione 21-acetate.
27. 14a,17u-methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy- 140:,17a-(p-isopropylbenzylidenedioxy) 4 pregnene-3, 20-dione ZI-acetate.
28. 14u,17m methylenedioxypregnane derivative according to claim 1 in which the derivative is 11/9, 21-dihydroxy 14a,17a (pmethoxybenzylidenedioxy)-4-pregnene-3,20-dione 21-acetate.
29. 14a,17a methylenedioxypregnane derivative according to claim 1 wherein R represents a phenyl-loweralkyl group, a cyclopropyl, furyl or thienyl group.
30. 1104,170: methylenedioxypregnane derivative according to claim 11 in which the derivative is 11,8,21-dihydroxy-14u,17a-((3'-pheny1propylidenedioxy 4 pregnene-3,20-dione 21-acetate.
31. 14a,17u methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,21-dihydroxy-14a,17a cyclopropylmethylenedioxy 4 pregnene-3,20-dione ZI-acetate.
32. 14ot,17a methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy-14a,17:1-(2'-furylmethylenedioxy) 4 pregnene- 3,20-dione.
33. 14a,17ot methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,3,21-dihydroxy-14a,17a-(2'-furylmethy1enedioxy) 4 pregnene- 3,20-dione 21- acetate.
34. :,1704 methylenedioxypregnane derivative according to claim 1 in which the derivative is 11,8,21-dihydroxy-14u,1711-(2'-thienylmethylenedioxy) 4 pregnene- 3,20-dione 2l-acetate.
35. 140:,170: methylenedioxypregnane derivative according to claim 1 in which the derivative is llpLZI-dihydroxy-14a,17a-nonylidenedi0xy 4-pregnene 3,20 dione 21-acetate.
36. 14LZ,17OC methylenedioxypregnane derivative according to claim 1 in which the derivative is 11fi,21-dihydroxy-14a,17a-(3' methoxycarbonylpropylidenedioxy)- 4pregnene-3,20-dione 21-acetate.
37. 14ot,17a methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroXy-14a,17ot- (1-naphthylmethy1enedioxy) 4 pregnene-3,20-dione 21-acetate.
38. 14a,17x methylenedioxypregnane derivative according to claim 1 in which the derivative is 115,21-dihydroxy-14a,17a cyclohexylmethylenedioXy-4-pregnene-3, 20-dione 21-acetate.
39. 1406,1706 methylenedioxypregnane derivative according to claim 1 in which the derivative is ZI-hydroxyl4u,17a-ethylidenedioxy 90,11fi dichloro-1,4-pregnadiene-3,20-dione 21-acetate.
40. 14ot,17ot methylenedioxypregnane derivative according to claim 1 in which the derivative is ZI-hydroxy- 14a,17a-ethylidenedioXy 4 pregnene-3,1l,20-tri0ne.
41. 14a,17a methylenedioxypregnane derivative according to claim 1 in which the derivative is 21-hydroxyl4u,l7a-ethylidenedioxy 4 pregnene-3,11,20-trione 21- acetate.
References Cited Djerassi: Steroid Reactions, p. 70-71 (1963).
HENRY A. FRENCH, Primary Examiner US. Cl. X.R.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL6808047A NL6808047A (en) | 1968-06-07 | 1968-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3629243A true US3629243A (en) | 1971-12-21 |
Family
ID=19803848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US831824A Expired - Lifetime US3629243A (en) | 1968-06-07 | 1969-06-05 | 14alpha 17alpha-methylenedioxypregnane derivatives |
Country Status (17)
Country | Link |
---|---|
US (1) | US3629243A (en) |
AT (1) | AT306933B (en) |
BE (1) | BE734180A (en) |
BR (1) | BR6909374D0 (en) |
CA (1) | CA944758A (en) |
CH (1) | CH548991A (en) |
DE (1) | DE1928429C3 (en) |
DK (1) | DK121436B (en) |
ES (1) | ES368120A1 (en) |
FR (1) | FR2010397A1 (en) |
GB (1) | GB1269160A (en) |
IE (1) | IE33147B1 (en) |
IL (1) | IL32307A (en) |
IT (1) | IT1044716B (en) |
NL (1) | NL6808047A (en) |
NO (1) | NO132236C (en) |
SE (1) | SE364266B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905962A (en) * | 1970-03-06 | 1975-09-16 | Arthur Friedrich Marx | Oestratrienes |
FR2412515A1 (en) * | 1977-12-22 | 1979-07-20 | Union Carbide Corp | PROCESS FOR THE PRODUCTION OF ALKYLENEGLYCOLS BY HYDROLYSIS OF ALKYLENE CARBONATES |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2451971A1 (en) * | 1974-10-31 | 1976-05-13 | Schering Ag | NEW PREGNAN 21 ACID DERIVATIVES |
GB2152783A (en) * | 1984-01-07 | 1985-08-07 | Ivan Manners Pick | Telephone handset aid |
-
1968
- 1968-06-07 NL NL6808047A patent/NL6808047A/xx unknown
-
1969
- 1969-05-28 IL IL32307A patent/IL32307A/en unknown
- 1969-05-30 BR BR209374/69A patent/BR6909374D0/en unknown
- 1969-06-04 DE DE1928429A patent/DE1928429C3/en not_active Expired
- 1969-06-05 SE SE07972/69A patent/SE364266B/xx unknown
- 1969-06-05 US US831824A patent/US3629243A/en not_active Expired - Lifetime
- 1969-06-06 DK DK308469AA patent/DK121436B/en not_active IP Right Cessation
- 1969-06-06 IE IE776/69A patent/IE33147B1/en unknown
- 1969-06-06 IT IT52139/69A patent/IT1044716B/en active
- 1969-06-06 NO NO2345/69A patent/NO132236C/no unknown
- 1969-06-06 AT AT537169A patent/AT306933B/en not_active IP Right Cessation
- 1969-06-06 FR FR6918808A patent/FR2010397A1/fr active Pending
- 1969-06-06 BE BE734180D patent/BE734180A/xx not_active IP Right Cessation
- 1969-06-06 CA CA053,640A patent/CA944758A/en not_active Expired
- 1969-06-06 GB GB28884/69A patent/GB1269160A/en not_active Expired
- 1969-06-07 ES ES368120A patent/ES368120A1/en not_active Expired
- 1969-06-09 CH CH869669A patent/CH548991A/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905962A (en) * | 1970-03-06 | 1975-09-16 | Arthur Friedrich Marx | Oestratrienes |
FR2412515A1 (en) * | 1977-12-22 | 1979-07-20 | Union Carbide Corp | PROCESS FOR THE PRODUCTION OF ALKYLENEGLYCOLS BY HYDROLYSIS OF ALKYLENE CARBONATES |
Also Published As
Publication number | Publication date |
---|---|
IE33147B1 (en) | 1974-04-03 |
BE734180A (en) | 1969-12-08 |
IT1044716B (en) | 1980-04-21 |
CH548991A (en) | 1974-05-15 |
NL6808047A (en) | 1969-12-09 |
NO132236B (en) | 1975-06-30 |
CA944758A (en) | 1974-04-02 |
IL32307A0 (en) | 1969-07-30 |
NO132236C (en) | 1975-10-08 |
FR2010397A1 (en) | 1970-02-13 |
AT306933B (en) | 1973-04-25 |
ES368120A1 (en) | 1971-05-01 |
DE1928429B2 (en) | 1974-10-24 |
DK121436B (en) | 1971-10-18 |
GB1269160A (en) | 1972-04-06 |
DE1928429A1 (en) | 1970-02-12 |
SE364266B (en) | 1974-02-18 |
BR6909374D0 (en) | 1973-03-13 |
DE1928429C3 (en) | 1975-06-12 |
IE33147L (en) | 1969-12-07 |
IL32307A (en) | 1972-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3048581A (en) | Acetals and ketals of 16, 17-dihydroxy steroids | |
US3652554A (en) | Halogen-pregnadienes | |
US2897218A (en) | 6-methyl-1-dehydro analogues of cortisone, hydrocortisone and 21-esters thereof | |
US3232839A (en) | delta1, 4-16alpha-methyl steroids | |
US3499016A (en) | 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series | |
US3629243A (en) | 14alpha 17alpha-methylenedioxypregnane derivatives | |
US2940968A (en) | Dimethylated steroids and processes for producing same | |
US3004994A (en) | 6alpha, 16alpha-dimethyl-pregnenes | |
US3065239A (en) | Novel 16-halomethyl steroids and processes | |
US3050519A (en) | Cyclocarbonate esters of 16alpha, 17alpha-dihydroxypregnenes | |
US2897217A (en) | 6-methyl analogues of cortisone, hydrocortisone and 21-esters thereof | |
US3707537A (en) | 4-chloro-4,6-diene-6-halo or lower alkyl steroids | |
US3189604A (en) | 6-fluoromethyl steroid compounds and process | |
US3116289A (en) | 20-keto-17, 21-alkylidenedioxy steroids and processes for their manufacture and transformation | |
US3585192A (en) | New estrane derivatives | |
US3116304A (en) | 15-alkyl steroids | |
US2867634A (en) | 11-oxygenated 6-methyl-pregnadienes | |
US3094523A (en) | 6alpha, 16alpha-dialkyl steroid intermediates and proceses | |
US3784603A (en) | 6-azido-21-oxygenated-steroids of the pregnane series,methods for their manufacture and intermediates produced thereby | |
US3069420A (en) | 16alpha, 17alpha-cyclocarbonate esters of 16alpha, 17alpha-dihydroxy steroids | |
US2942012A (en) | 16-keto steroids of the pregnane series and methods for making same | |
US3005838A (en) | 6alpha, 16alpha-dimethyl-11-oxygenated-17alpha-hydroxy-unsaturated-pregnane-3, 20-diones | |
US3257388A (en) | 6-difluoromethyl and 6-trifluoromethyl delta-pregnadienes and the 16alpha, 17alpha acetonides thereof | |
US3251834A (en) | Process for the production of 6-difluoro methyl hydrocortisone and intermediates obtaned therefrom | |
US3321496A (en) | 16alpha-halo methyl-saturated steroids of the pregnane series |